Nazim Serdar Turhal M

Transkript

Nazim Serdar Turhal M.D.
Personal Information
Date of Birth:
Place of Birth:
Citizenship:
Work Address:
Office:
Telephone:
Fax:
e-mail:
April 5th, 1964
Eskisehir, Turkey
T.R. / U.S.A.
Tophanelioglu cad. 13/15 Altunizade Istanbul 81190
Unel Apt 251/5 Bagdat Cad Goztepe Istanbul 34728
90 (216) 3580238-39-40 (pbx)
90(216) 3580237
[email protected]
Present Academic Rank and Position:
Education:
Professor,
Marmara University Medical School
Director,
Dept. of Internal Medicine,
Division of Oncology,
Marmara University Hospital
September 1988
M.D. Univ. of Istanbul
1988-89
Visiting Extern
U.C. San Francisco
San Francisco, Ca.
Surgical Intern
Baptist Med. Ctr.
Birmingham, Al.
Internal Medicine Resident
Griffin Hospital
(Yale U. Affiliate)
Derby, Ct.
Hematology-Oncology Fellow
Mt.Sinai Med. Center
New York, N.Y.
Bone Marrow Transplant Fellow
Mt. Sinai Med. Center
New York, N.Y.
1989-90
1990-93
1993-96
1996-97
Board Certification:
ECFMG:
FLEX:
Internal Medicine (USA):
Oncology (USA):
Renewed
Internal Medicine (Turkish)
Oncology (Turkish)
Oncology (European)
April 1989
June 1990
November 1996
November 1997
November 2007
October 1996
August 1997
January 2000
428514-4
640405501
158365
158365
158365
42248-46399
43335-46399
2
Medical Licensure
New York
Tennessee
192309
034693
Honors:
2000
Technology Transfer Grant Recipient
ESMO-NCI Milan
Chief Fellow
Mt. Sinai Med. Center
Representative Class of '89
Warsaw, Poland
Representative Class of '88
K. City, Kuwait
American Field Service Student
Nebraska, USA
1994-95
1987
1986
1981-82
Previous Professional Positions and Appointments
Outside of present position I covered numerous physicians and locations in United
States for locum tenants appointments since 1997.
Education-Teaching
1.
2.
3.
4.
Weekly junior medical student bed side teaching
Quarterly junior medical student oncology lectures
Biweekly Oncology seminars to fellows and residents
Weekly Cancer care meetings with nurses,
residents, fellows, psychologists
5. Weekly junior medical student modular
educational activities
3 hours
8 hours
4 hours
1997-present
1997-present
1997-present
4 hours
1997-present
48 hours
1999-present
Postdoctoral Fellows Working or Worked For Me
Gul Atalay M.D.
Faysal Dane
Devrim Cabuk
Mehmet Teomete
Mahmut Gumus
Mehmet Aliustaoglu
Meltem Ekenel
Salih İyikesici
Hatice Yildiz
Esen Guzet
Neslihan Doygun
Fatih Ergun
Sibel Çelebioğlu
6 years
4 years
2 years
2 years
3 years
3 years
3 years
3 years
1 year
2 years
2 years
2 years
1 year
Med. Oncology
Med. Oncology
Med. Oncology
Med. Oncology
Med. Oncology
Med. Oncology
Med. Oncology
Med. Oncology
Data Management
Data Management
Data Management
Data Management
Data Management
3
Institutional, Departmental, and Divisional Administrative Responsibilities,
Committee Memberships, and Other Activities
Director
Credentialing Coordinator
Faculty of Pharmacy Medical
Lectures Coordinator
Transfusion Committee
Hospital Formulary
Division of Oncology
Department of Medicine
1998-present
2000-present
Medical School
Marmara Univ. Hospital
Marmara Univ. Hospital
2000
1999
1999
Professional and Society Memberships
American Society of Clinical Oncology
European Society of Medical Oncology
Balkan Union of Oncology
American College of Physicians
Turkish Oncological Society
1999
1999
1998
1998
1998
Intramural Presentations
1.
2.
3.
4.
5.
Weekly Cancer Grand Rounds
Weekly multidisciplinary patient care meetings
Weekly oncological pathology meetings
Quarterly Internal Medicine grand rounds
Weekly Thoracic malignancies multidisciplinary
patient care meetings
6. Oncology Nursing Regional Conference
7. Surgical Oncology Nursing PhD Program
8. Oncology Nursing National Conference
1 hour
3 hours
2 hours
1 hour
1998199819981998-
2 hours
31 hours
12 hours
32 hours
19992000
2000
2001
Clinical Practice, Interests and Accomplishments
Active member of EORTC Gastrointestinal tumors study group.
Research Interests
Prognostic factors and therapy in Gastrointestinal malignancies
Research Grants Awarded
1. Marmara University research grant for mamosintigraphy project
2. European Society for Medical Oncology Technology Transfer grant
Community Activities
1. “Living with Cancer” television series at Medical Channel
2. “Living with Cancer” column at weekly Gazette Kadikoy
2001- 02
2001- 03
4
Bibliography
International Peer Reviewed Journal Publications:
2.3.1.1. Turhal N, Sullivan MB, Blakemore WS. Thyroglossal Duct Cyst. South Med J, 1990,
83:8, 983-4.
2.3.1.2. Turhal N, DeLuca VA Jr. Ulcerative Colitis and Scleroderma. A coincidental
relationship. J Clin Gastroenterol. 1994, 18:3, 218-9.
2.3.1.3. Turhal NS, Henehan MD, Kaplan KL. Multiple myeloma: a patient with unusual features
including intracranial and meningeal involvement, testicular involvement, organomegaly, and
plasma cell leukemia. Am J Hematol 1998, 57:1, 51-56.
2.3.1.4. Turhal NS. Cyclosporin A and Imipenem Associated Seizure Activity in Allogeneic Bone
Marrow Transplantation Patients. Journal of Chemotherapy 1999 11(5): 410-413.
2.3.1.5. Turhal NS, Erdal S, Karacay S. Efficacy of the Treatment to Relieve Mucositis Induced
Discomfort. Supportive Care in Cancer 2000 8(1): 55-58.
2.3.1.6. Turhal NS. Pancreatic Duct Cell Carcinoma with Positive In-111 Octreotide Uptake.
Journal of Experimental and Clinical Cancer Research 2000 19(2): 241-244.
2.3.1.7. Turhal NS. Sumatriptan overdose in episodic cluster headache: a case report of overuse
without event. Cephalalgia. 2001 21:700.
2.3.1.8. Turhal NS, Rand J. Antiphospholipid syndrome in HIV infection - Report of four cases
and review of literature. Allergy & Clinical Immunology International 2001 13(6):1-4.
2.3.1.9. Duman D, Turhal NS, Duman DG, M.D. Fatal Aplastic Anemia during Treatment with
Ketoconazole. American Journal of Medicine 2001, 111:9
2.3.1.10. Turhal NS. Two cases of advanced renal cell cancer with prolonged survival of 8 and 12
years. Japanese Journal of Clinical Oncology 2002 32(4): 152-153
2.3.1.11. Turhal NS, Gumus M, Atalay G, Aliustaoglu M, Kabakas F, Karamanoglu A, Sengoz
M. Outpatient cancer care in a Turkish university hospital. Journal of BUON 2002 7(4): 397-398.
2.3.1.12. Turhal NS, Efe B, Gumus M, Aliustaoglu M, Karamanoglu A, Sengoz M. Patient
satisfaction in the outpatients` chemotherapy unit of Marmara University, Istanbul, Turkey: a staff
survey. BMC Cancer 2002 2(1): 30-33.
2.3.1.13. Turhal NS, Aliustaoglu M, Gurses I, Gumus M, Atalay G, Karamanoglu A, Sengoz M.
Neoplastic diseases prevalence in a Turkish university hospital. Journal of BUON 2003 8(1): 4548.
2.3.1.14. Karamanoglu A, Yumuk PF, Gumus M, Aliustaoglu M, Selimen D, Sengoz M, Turhal
NS. Port needles: Do they need to be removed as frequently in infusional chemotherapy? Journal
of Infusional Nursing 2003 26(4):239-242.
2.3.1.15. Abacıoglu U, Sengoz M, Yumuk F, Salepci T, Turhal NS. Cisplatin and etoposide in
extra pulmonary small cell cancer. Tumori 2003 89(3): 274-277.
2.3.1.16. Yumuk PF, Abacioglu U, Caglar H, Gumus M, Sengoz M, Turhal NS. Outcome of
5
rectum and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in Marmara
University Hospital. J Chemother 15 (6): 603-606, 2003.
2.3.1.17. Turhal NS, Dane F, Dede F, Gumus M, Yumuk PF, Cakalagaoglu F, Savcı D, Karaman
M, Gulluoglu B, Turoglu HT. 99m-Tc-MDP Scintimammography to assess angiogenesis in
patients with untreated breast cancer. Anticancer Research. 24:1999-2006 (2004)
2.3.1.18. Yumuk PF, Gumus M, Ekenel M, Basaran G, Aliustaoglu M, Topal A, Turhal NS, N.
Attitude Toward Genetic Testing in Turkish Society. Genetic Testing 8(2):169-173, 2004
2.3.1.19. Yumuk PF, Aydin SZ, Dane F, Gumus M, Ekenel M, Aliustaoglu M, Karamanoglu A,
Sengoz M, Turhal NS. The absence of early diarrhea with atropine premedication during
irinotecan therapy in metastatic colorectal patients. International Journal of Colorectal Disease
19: 609-610, 2004.
2.3.1.20. Bolukbas FF, Kılıc H, Bolukbas C, Gumus M, Horoz M, Turhal NS, Kavalı B. Serum
leptin concentration and advanced gastrointestinal cancers: a case controlled study. BMC Cancer
2004, 4:29-32.
2.3.1.21. Yumuk PF, Abacioglu U, Demir G, Cabuk D, Dane F, Gumus M, Ozguroglu M, Ekenel
M, Basaran G, Turhal NS. Does the Incidence of Anal Canal Cancers Differ in Moslem
Societies? International Journal of Colorectal Disease, Clinical and Molecular Gastroenterology
and Surgery. 20(1), 76 2004.
2.3.1.22. Aliustaoglu M, Yumuk PF,Gumus M, Ekenel M, Bolukbas F, Mutlu N, Basaran G,
Avsar E, Turhal NS. D-Dimer—Can it be a marker for malignant gastric lesions. Acta
Oncologica, 2004 Dec 43(8) 770-771.
2.3.1.23. Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M,
Turhal NS, Stuart R, Van Cutsem E, D’Haese S, Coens C. Clinical and Psychometric validation
of a questionnaire module, The EORTC QLQ-STO 22, to assess quality of life in patients with
gastric cancer. Eur J Cancer, 2004 Oct 40(15): 2260-8
2.3.1.24. Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar H,
Sengoz M, Turhal S. What should be the optimal number of lymph nodes dissected in colorectal
Cancer surgery? Tumori, 172/03. 11 2004.
2.3.1.25. Yumuk PF, Turhal NS, Gumus M, Hatabay NF, Turken O, Ozkan A, Salepci T,
Aliustaoglu M, Ahiskali R, “Results of paclitaxel (day 1 and 8) and Carboplatin given on every
three weeks in advanced (stage III-IV) non-small cell lung Cancer”, BMC Cancer,
(MS:7372801141679098), 2005 March, 21
2.3.1.26. Abacioğlu U, Yumuk PF, Caglar H, Sengoz M, Turhal NS, “Concurrent
chemoradiotherapy with low dose weekly Gemcitabine in stage III non-small cell lung cancer.”
BMC Cancer. 2005 Jul, 6;5:71
2.3.1.27. Yumuk PF, Turhal NS, Gumus M, Hatabay NF, Turken O, Ozkan A, Salepci T,
Aliustaoglu M, Ahiskali R. Results of Paclitaxel (day 1 and 8) and carboplatingiven on every three
weeks in advanced (stage III-IV) non-small cell lung cancer. BMC Cancer. 2005 Jan 25;5:10.
2.3.1.28. Yumuk PF, Abacioglu U, Demir G, Cabuk D, Dane F, Gumus M, Ozguroglu M, Ekenel
M, Basaran G, Turhal NS, Does the incidence of anal canal cancers differ in Moslem societes?
International Journal of Colorectal Disease 2005 20:76
6
2.3.1.29. Turhal NS, Popov I. Colorectal cancer care in the Balkan countries. Journal of Balkan
Union of Oncology Volume 10 No: 2, April-June 2005 189-193
2.3.1.30. Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar H,
Sengoz M, Turhal NS, What is the optimal number of lymph nodes to be dissected in colorectal
cancer surgery? Tumori. 2005 Mar-Apr;91(2): 168-72
2.3.1.31. Abacioglu U, Yumuk PF, Caglar H, Sengoz M, Turhal NS, Concurrent
chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer.
BMC Cancer, 2005 Jul 6;5:71
2.3.1.32. Onol FF, Tanidir Y, Kotiloglu E, Bayramicli M, Turhal NS, Turkeri LN. “Proximal type
epithelioid sarcoma of the scrotum: a source of diagnostic confusion that needs immediate
attention.” Eur Urol. 2006 Feb; 49(2):7. Epub 2005 Nov 7.
2.3.1.33. Turhal NS, Popov IP. “Colorectal cancer care in the Balkan countries.” J BUON 2005
Apr-Jun;10(2):189-93
2.3.1.34. Onol FF, Tanidir Y, Kotiloglu E, Bayramicli M, Turhal NS, Turkeri LN. “Proximal type
attention: Part 2.” Eur Urol 2006 Mar 49(3):578-80.
2.3.1.35 Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G, Kaya H,
Barisik N, Turhal NS. “HPV DNA frequency and subset analysis in human breast cancer patients
normal and tumoral tissue samples.” J Exp Clin Cancer Res. 2006 Dec;25(4):515-21.
2.3.1.36. Onol FF, Tandr Y, Kotiloglu E, Bayramicli M, Turhal NS, Turkeri LN. Proximal type
attention. Part 1: Eur Urol 2006 Feb;49(2): 406-7
2.3.1.37. Onol FF, Tandr Y, Kotiloglu E, Bayramicli M, Turhal NS, Turkeri LN. Proximal type
attention. Part 2: Eur Urol. 2006 Mar; 49(3):578-80.
2.3.1.38. Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G, Kaya
H, Barisik N, Turhal NS. HPV DNA frequency and subset analysis in human breast cancer
patients normal and tumoral tissue samples. Journal of Experimental and Clinical Cancer
Research, December 2006, 515-521
2.3.1.39. Komurcu S, Turhal NS, Altundag K, Atahan L, Turna HS, Manavoglu O, Yavuz AA,
Ozkok S, Aliustaoglu M, Altinbas M, Pak Y, Cooper R, Yaylaci M, Demirkan B, Sarihan S,
Ozdemir F. “Safety and efficacy of transdermal fentanyl in patients with cancer pain: phase IV,
Turkish Oncology group trial.” Eur J Cancer Care (Engl). 2007 Jan; 16(1):67-73
2.3.1.40. Atasoy BM, Abacioglu U, Dane F, Ozgen Z, Yumuk PF, Ozden S, Akgun Z, Mayadagli
A, Basaran G, Turhal NS, Sengoz M. “Concomitant administration of uracil-tegafur and
leucovorin during adjuvant radiotherapy for locally advanced rectal cancer.” J BUON. 2007 AprJun;12(2):203-8.
7
2.3.1.41. Celikel C, Eren F, Gulluoglu B, Bekiroglu N, Turhal NS. “Relation of neuroendocrine
cells to transforming growth factor-alpha and epidermal growth factor receptor expression in
gastric adenocarcinomas: prognostic implications.” Pathol Oncol Res. 2007:13(3):215-26. Epub
2007 Oct 7.
2.3.1.42. Cabuk D, Basaran G, Celikel C, Dane F, Yumuk PF, Iyikesici MS, Ekenel M, Turhal
NS. “Vascular Endothelial Growth Factor, Hypoxia-Inducible Factor 1 Alpha and CD34
Expressions in Early-Stage Gastric Tumors: Relationship with Pathological Factors and
Prognostic Impact on Survival.” Oncology. 2007 Nov 15;72(1-2):111-117.
2.3.1.43. Atasoy BM, Abacioglu U, Dane F, Ozgen Z, Yumuk PF, Ozden S, Akgun Z, Mayadagli
A, Basaran G, Turhal NS, Sengoz M. Concomitant administration of uracil-tegafur and
leucovorin during adjuvant radiotherapy for locally advanced rectal cancer. Journal of BUON 12:
203-208, 2007
2.3.1.44. Yumuk PF, Dane F, Yumuk VD, Yazici D, Ege B, Bekiroglu N, Toprak A, Iyikesici S,
Basaran G, Turhal NS.Impact of body mass index on cancer development. J BUON. 2008 JanMar;13(1):55-59
2.3.1.45. Atasoy BM, Dane F, Yumuk PF, Akgün Z, Turhal NS, Abacioğlu U, Sengöz M.
Toxicity and feasibility analysis for cisplatin-based concomitant chemoradiotherapy in locally
advanced nasopharyngeal carcinoma. J BUON. 2008 Jan-Mar;13(1):43-50.
2.3.1.46. Koldas M, Gumus M, Seker M, Seval H, Huyla K, Dane F, Kural A, Gumus A, Salepci
T. and NS Turhal, ”Thrombin-activatable fibrinolysis inhibitor levels in patients with non-smallcell lung cancer,” Clin Lung Cancer., 9(2), 112-115 (2008).
2.3.1.47. Ustaalioglu BB, Gumus M, Bilici A, Seker M, Dane F, Salepci T, S alman T, Aliustaoglu
M, Gezen C, Yaylaci M, Turhal NS, Neoadjuvant chemotherapy for locally advanced breast
cancer: a single center experience. Med. Oncol, 2009 Jun 2.
2.3.1.48. Kefeli U, Dane F, Yumu k PF, Karamanoglu A, Iyikesici M, Basaran G, Turhal NS,
Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted
port care in patients with cancer. Eur J Cancer Care (Engl), 2009 Mar; 18(2), 191-4.
2.3.1.49. Kuscu MK, Dural U, Onen P, Yasa Y, Yayla M, Basaran G, Turhal NS, Bekiroglu N.
The association between individual attachment patterns, the perceived social support, and the
psychological well-being of Turkish informal caregivers. Psychooncology, 2009 Jan 12.
2.3.1.50. Dane F, Ozturk MA, Tecimer T, Atasoy BM, Cabuk D, Yumuk PF, Basaran G, Teomete
M, Turhal NS. A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin’s lymphoma: The
importance of second opinion. J BUON, 2009 Apr-Jun;14(2):309-11.
2.3.1.51. Kefeli U, Dane F., Yumuk PF, Karamanoglu A, Iyikesici S, Basaran G, and NS Turhal,
“Prolonged inerval in prophylactic heparin flushing for maintenance of subcutaneous implanted
port care in patients with cancer,” Eur J Cancer Care (Engl), 18(2), 191-194 (2009).
2.3.1.52. Dane F, Ozturk MA, Tecimer T, Atasoy BM, Cabuk D, Yumuk PF, Basaran G, Teomete
M, and NS Turhal, “A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin’s lymphoma:
the importance of second opinion,” J BUON, (2009). [basımda]
8
2.3.1.53. Gumus M, Basak O, Ustaalioglu MG, Kiziltan E, Bilici A, Seker M, Erkol B, Salepci T,
Mayadagli A, Turhal NS. Factors that Affect Patients’ Decision-Making about Mastectomy or
Breast Conserving Surgery, and the Psychological Effect of this Choice on Breast Cancer
Patients. Breast Care 2010;5:164–168
2.3.1.54. Dane F, Yumuk PF, Başaran G, Gündüz F, Peker Ö, Turhal NS, A Case of Primary
Breast Mantle Cell Lymphoma with Atypical Relapse Patterns and Rewiew of the Literature
Journal of BUON Vol: 16 No: 2, 2010
2.3.1.55. Turhal NS, Bas E, Er O, Aliustaoglu M, Seber S, Dane F, Korkmaz T, Soyuer I, Ozkara
S, Celikel C. ERCC1 is not expressed in hepatocellular cancer: A Turkish Oncology Group,
Gastrointestinal Oncology Subgroup study. Journal of BUON 15: 794-796, 2010
2.3.1.56. Turhal NS. Dane F, Sınav H, Yalçın N, Khorshidi Z, Yalçın ZZ. Anxiety and depression
in Turkish breast cancer patients. Journal of BUON 15: 720-725, 2010
2.3.1.57. Korkmaz T, Seber S, Turhal NS. Primary melanoma of the gallbladder. Letter 802
2.3.1.58. Basaran G, Cabuk D, Caglar HB, Gulluoglu B, Kaya H, Seber S, Korkmaz T, Telli F,
Kocak M, Dane F, Yumuk PF, Turhal NS. Clinical outcome of breast cancer patients with N3a
(≥10 positive lymph nodes) disease: has it changed over years? Med Oncol. 2010 Apr 14. [Epub
ahead of print] DOI 10.1007/s12032-010-9516-1.
2.3.1.59. Dane F, Ozturk MA, Gumus M, Guven A, Aliustaoğlu M, Cabuk D, Teomete M, Basaran
G, Yumuk PF, Turhal NS. Effi cacy, safety and prognostic features of resected colon carcinoma
treated in “real world” practice: a retrospective cohort-study. Journal of BUON 16: 257-264,
2011
2.3.1.60. Bilici A, Dane F, Seker M, Ustaalioglu BB, Aliustaoglu M, Temiz S, Gezen C, Yavuzer
D, Aksu G, Mayadagli A, Gumus M, Uygun K, Turhal NS. Is Subdivision of pT2 Tumors Superior
to Lymph Node Metastasis for Predicting Survival of Patients with Gastric Cancer? Review of 224
Patients from Four Centers. Digestive Diseases And Scienses DOI: 10.1007/s10620-011-1721-z 2011.
2.3.1.61. Dane F, Akif Ozturk M, Gumus M, Guven A, Aliustaoglu M, Cabuk D, Teomete M,
Basaran G, Fulden Yumuk P, Turhal NS. Efficacy, safety and prognostic features of resected
colon carcinoma treated in "real world" practice: a retrospective cohort-study. J BUON. 2011
Apr-Jun;16(2):257-64.
2.3.1.62. Basaran G, Devrim C, Caglar HB, Gulluoglu B, Kaya H,Seber S, Korkmaz T, Telli,
Kocar M, Dane F, Turhal NS. Clinical outcome of breast cancer patients with N3a (≥10 positive
lymph nodes) disease: has it changed over years? Medical Oncology: Volume 28, Issue 3 (2011),
Page 726-732.
2.3.1.63. Korkmaz T, Seber S, Basaran G, Yumuk PF, Dane F, Kocar M, Telli F, Turhal NS. 5Flourouracil–Induced Encephalopathy in Parkinson’s disease. International Journal of
Hematology and Oncology 2011 vol: 21 Num 1 Page(s): 001-003
2.3.1.64. Abali H, Ata A, Ozdogan M, Turhal NS, Cabuk D, Seyrek E, Coskun HS, Arik Z,
Erman M, Celik I. Frequency of comorbid illnesses in cancer patients in Turkey. Journal of
BUON 16: 557-560, 2011.
2.3.1.65. Turhal NS, Dane F, Butur S, Kocak M, Telli F, Seber S, Kanitez M, Aktas B, Yumuk
PF. Efforts to Validate the Applicability of Established Chemotherapy Treatment in Turkish
Cancer Patient. Pharmaceutica Analytica Acta. S14. 2011.
9
2.3.1.66. Okutur K, Korkmaz T, Seber S, Dane F, İlhan M, Turnal NS, Demir G. Weekly
Docetaxel, Cisplatin and 5-Flourouracil in the first-line treatment of metastatic gastric cancer.
MOJ:1;35-40, 2011.
2.3.1. 67. Turhal NS. Daily life of a Turkish Medical Oncologist. J Oncol Pract 8:164-166, 2012
2.3.1.68. Korkmaz T, Seber S, Okutur K, Basaran G, Yumuk F, Dane F, Oney T, Polat O,
Madenci O, Demir G, Turhal NS. Serum thymidine kinase 1 levels correlates with FDG uptake
and prognosis in patients with non small cell lung cancer. Biomarkers, 2012; Early Online: 1–7 ©
2012 Informa UK, Ltd.
2.3.1.69. Turhal NS et al. The Association between Socio-Demographic Parameters and the Use
of Complementary Interventions in Cancer Patients in Turkey A Turkish Oncology Group Study.
Journal of Cancer Therapeutics and Research, ISSN: 2049-7962, Volume: 1, Issue: 1, 2012
10
National (Turkish) Publications:
2.3.2.1. Turhal NS. “Metastatik meme kanseri yaygın kemik metastazlarında tedavi”,
Kanser Gündemi, Türkiye Kanserle Savaş Vakfı, 1998 3(3): 118-121.
2.3.2.2. Turhal NS. “Yetişkin kanser hastalarında transfüzyon tedavisi yaklaşımları”
Damla, Kan Merkezleri ve Transfüzyon Derneği Bülteni, 1998 22:4-7.
2.3.2.3. Turhal NS. “Meme kanserinin biyolojik tedavisinde: Herceptin, Academic
Hospital 1998 4:16-18.
2.3.2.4. Turhal NS, Tanju P, Pekin S. “Serviks kanseri etyolojisine yönelik standart ve
gelecek vadeden tarama yaklaşımları” Hekimler Birliği Vakfı, Türkiye Klinikleri,
Jinekolojik Obstetrik, 1999 9(3): 215-220.
2.3.2.5. Turhal NS, Akdas A. “Prostat kanserinde gen tedavisi uygulaması ve sorunları”
Üroloji Bülteni 1999 10(1): 5-11.
2.3.2.6. Turhal NS. “Lokal ileri evre meme kanserinde neoadjuvan ve adjuvan
kemoterapi” Hematoloji-Onkoloji, Güncel Derleme Dergisi, 2001 3(2):123-127.
2.3.2.7. Atalay G, Turhal NS. “Kanserli hastalarda ağrı dışı semptomların palyasyonu:
Hıçkırık, disfaji ve dispepsi” Hematoloji-Onkoloji, Güncel Derleme Dergisi, 2001, 3(3):
236-239.
2.3.2.8. Kaya H, Kotiloglu E, Sengoz M, Turhal S, Uneri C. “Aggressive fibromatosis: A
case report”. Journal of Marmara University Dental Faculty, 2001 Vol 4(3): 288-90.
2.3.2.9. Basaran G, Ekenel M, Demirkalem P, Cakır T, Gulluoglu B, Gumus M, Dane F,
Iyikesici S, Kaya H, Yumuk PF, Turhal NS. “Evre 1 (T1 N0 M0) Meme Kanseri:
Patolojik özellikler ve klinik sonuçlar”, Türk Onkoloji Dergisi, 2004 19(2):53-57.
2.3.2.10. Yumuk PF, İyikesici MS, Gumus M, Aliustaoglu M, Dane F, Basaran G, Ekenel
M, Abacıoglu U, Turhal NS. “Lokal ileri ve metastatik küçük hücreli dışı akciğer kanseri
hastalarının değerlendirilmesi, Marmara Üniverstesi deneyimi“, Türk Onkoloji Dergisi,
2004 19(3): 106-110.
2.3.2.11. Yumuk PF, Turhal NS. “Bir medikal onkolog perspektifinden muskuloskeletal
hastalıklarda nükleer tıp” Turkish Journal of Nuclear Medicine 2004, Baskıda
2.3.2.12. Atasoy BM, Dane F, Sarı M, Yumuk PF, Akgün Z, Turhal NS, Abacıoğlu U, ve
Şengöz M, “Lokal ileri evre skuamöz hücreli baş ve boyun kanserinde sisplatinle eş
zamanlı kemoradyoterapi: Yan etki ve uygulanabilirlik analizi,” Türk Onkoloji Dergisi, 23,
1-11 (2008).
2.3.2.13. Atasoy BM, Dane F, Çağlar H, Tezcanlı E, Cingi A, Abacıoğlu U, Turhal NS, ve
C Yeğen, “Rezeke edilebilir lokal ileri evre rektum kanserinde floroprimidin bazlı
11
kemoterapi ile eş zamanlı ameliyat öncesi radyoterapi,” Türk Onkoloji Dergisi, 23, 163171 (2008).
2.3.2.14. Atasoy BM, Dane F, Kefeli AÜ, Caglar H, Cingi A, Turhal NS, Abacıoglu U, Yegen C.
Concomitant chemoradiotherapy with low-dose weekly Gemcitabine for nonmetastatic
unresectable pancreatic cancer. The Turkish Journal of Gastroenterology 2011;22(1):60-64
12
Citations:
2.3.3.1. Author(s): Kim JH; Lee SH; Park J; Kim HY; Lee SI; Nam EM; Park JO; Kim
K; Jung CW; Im YH; Kang WK; Lee MH; Park K. Title: Extrapulmonary small-cell
carcinoma: a single-institution experience. Source: JAPANESE JOURNAL OF
CLINICAL ONCOLOGY 2004, Vol 34, Iss 5, pp 250-254
2.3.3.2. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, Liu Z, Tan D, Cheng L,
Hatem F, Huang J, Anthony S. Title: Small Cell Carcinoma of the Prostate: An
Immunohistochemical Study. Source: American Journal of Surgical Pathology.
30(6):705-712, June 2006
2.3.3.3. Author(s): D. Demellawy, A. Samkari, M. Sur, F. Denardi, S. Alowami. Title:
Primary small cell carcinoma of the cecum. Source: Annals of Diagnostic
Pathology, Volume 10, Issue 3, Pages 162-165
2.3.3.4. Author(s): Young HK, Ryuk K, Ghap JJ, Myung HR, Sang YH, Hyuk CK, Jin
SJ, Tae BS, Jong YO, Ki NL. Title: Extrapulmonary small-cell carcinoma of the liver
Source: Journal of Hepato-Biliary-Pancreatic Surgery Oct. 2004 Vol 11, Num 5,
2.3.3.5. Author(s): Vogelsang H., Siewert I.R. Title: Neuroendokrine Tumors of the
hindgut Source: Best Practice & Research Clinical Gastroenterology, Volume 19, Issue
5, Pages 739-751
2.3.3.6. Author(s): A. Ferlito, K. Devaney, A. Rinaldo Title: Neuroendocrine neoplasms
of the larynx: Advances in identification, understanding, and management Source: Oral
Oncology, Volume 42, Issue 8, Pages 770-788
2.3.3.7. Author(s): E. Kurt, C. Sezgin, T. Evrensel, U. Yalcinkaya, O. Kanat, A. Veral,
M. Demiray, M. Arslan, B. Karabulut, I. Ercan, E. Goker, O. Manavoglu Title: Therapy,
outcome and analysis of c-kit expression in patients with extrapulmonary small cell
carcinoma Source: International Journal of Clinical Practice; 2005; 59 (5), 537–543.
2.3.3.8. Author(s): Chen JW , Yuan L , Hu HH Title: Small cell undifferentiated
carcinoma in the epididymis Source: Chinese Medical Journal 2005; 118(16): 1402-1404
2.3.3.9. Author(s): Author(s): Vogelsang H., Siewert I.R. Title: Neuroendokrine
Tumoren des Kolons und Rektums, Mit Ausnahme der Appendix Source: MULTİ
MODALİTY TREATMENT RESULTS Onkologe 2004-10:1069-1078
2.3.3.10. Author(s): Kim KO; Lee HY; Riyu MH; Shin SJ; Kim MK; Lee KH; Hyun MS;
Bae HS; Ryoo HM. Title: Extrapulmonary small-cell carcinoma Source: J Korean Med.
Sci. 2006; 21: 833-7
2.3.3.11. Author(s): Lee SS; Lee JL; Riyu HM; Chang HM; Tae WK; Jung SL; Jang SJ;
Khang SK; Kang YK Title: Extrapulmonary small cell carcinoma: Single center
experience with 61 patients Source: Acta Oncologica, Volume 46, Issue 6 2007 , pages
846 – 851
2.3.3.12. Author(s): M. Yashi, F. Terauchi, A. Nukui, M. Ochi, M. Yuzawa, Y. Hara, T.
Morita Title: Small-cell neuroendocrine carcinoma as a variant form of prostate cancer
13
recurrence: A case report and short literature review Source: Urologic Oncology:
Seminars and Original Investigations, Volume 24, Issue 4, Pages 313-317
2.3.3.13. Author(s): A Barbeaux, L Duck, B Weynand, G Desuter, M Hamoir,
V Gregoire, J Baurain, J Machiels Title: Primary combined squamous and small cell
carcinoma of the larynx: report of two cases and discussion of treatment modalities
Source: Oto-Rhino-Laryngology, 2006; Volume 263, Number 8 / 786-790
2.3.3.14. Author(s): L Kovac, M Gjuric, S Branica, K Dawidowsky, S Seiwerth Title:
Small cell neuroendocrine carcinoma in the petrous apex Source: Journal of Laryngology
& Otology (2006), 120: 74-76
2.3.3.15. Author(s): N. Güler, P. Yumuk, D. Ilguy, V. Olgac, J. Greer Title: Limited
Painful Mouth Opening Source: Journal of Oral and Maxillofacial Surgery, Volume
63, Issue 8, Pages 1201-1205
2.3.3.16. Author(s): R. Simon, P. Bourne, Q. Yang, B. Spaulding, P. di Sant'Agnese, H.
Wang, H. Xu Title: Extrapulmonary small cell carcinomas express K homology domain
containing protein overexpressed in cancer, but carcinoid tumors do not Source: Human
Pathology, Volume 38, Issue 8, Pages 1178-1183
2.3.3.17. Author(s): WT hsueh, WC Su, FF Chen Title: Experiences of Radiotherapy on
Extrapulmonary Small Cell Carcinoma Source: 2005, 2, 24.
2.3.3.18. Author(s): DE Demellawy, MA Khalifa, N Ismiil, S Wong, Z Ghorab Title:
Primary colorectal small cell carcinoma: A clinicopathological and immunohistochemical
study of 10 cases Source: Diagn Pathol. 2007; 2: 35.
2.3.3.19. Author(s): Yuan ZY, Guan ZZ, Zhou ZM, Xia Y, Huang WZ, Yang XL.Title:
Extrapulmonary small cell carcinoma in 52 patients Source: Chinese Medical Journal
2006 Sep; 25(9): 1131-3.
2.3.3.20. Author(s): G. Lima, I. Varkarakis, M. Allaf, S. Fine, L. Kavoussi Title: Small
cell carcinoma of epididymis: Multimodal therapy Source: Urology, Volume 66, Issue
2, Pages 432.e19-432.e20
2.3.3.21. Author(s): AF Korcum; G Aksu; M Ozdogan; G Erdogan; O Taskin Title:
Stage I small cell carcinoma of the endometrium: survival and management options
Source: Acta Obstetricia et Gynecologica Scandinavica, 200
2.3.3.22. Author(s): EB. Rubenstein, DE Peterson, M Schubert, D Keefe, D McGuire, J
Epstein, LS. Elting, PC. Fox, C Cooksley, ST. Sonis,Title: Clinical practice guidelines for
the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis
Source: Cancer 2004 Volume 100, Issue S9 , Pages 2026 – 2046
2.3.3.23. Author(s): PJ Hancock, JB Epstein, GR Sadler Title: Oral and dental
management related to radiation therapy for head and neck cancer Source: J Can Dent
Assoc 2003, Vol 69 No: 9, 585-590
14
2.3.3.24. Author(s): DB. McGuire, ME Correa, J Johnson, P Wienandts, Title: The role
of basic oral care and good clinical practice principles in the management of oral
mucositis Source: Supportive Care in Cancer 2006, Vol 14, No 6, 541-547
2.3.3.25. Palliative Medicine Handbook 3. Dr lan Back 2001
2.3.3.26. Author(s): DJ Harris, MT Knobf, Title: Assessing and Managing
Chemotherapy-Induced Mucositis Pain Source: Clinical Journal of Oncology Nursing,
2004, Vol 8, No 6, 622-628
2.3.3.27. Author(s): EMB Costa; MZ Fernandes; LB Quinderé; LB Souza; LP Pinto
Title: Evaluation of an oral preventive protocol in children with acute lymphoblastic
leukemia Source: Pesqui. Odontol. Bras. 2003;17(2):147-50
2.3.3.28. Author(s): D. Alterio, B. Jereczek-Fossa, G. Zuccotti, M. Leon, E. Omodeo
Sale, M. Pasetti, T. Modena, P. Perugini, L. Mariani, R. Orecchia Title: Tetracaine oral
gel in patients treated with radiotherapy for head-and-neck cancer: Final results of a phase
II study Source: International Journal of Radiation Oncology*Biology*Physics, Volume
64, Issue 2, Pages 392-395
2.3.3.29. Author(s): B Quinn, C.M.J. Potting, R Stone, N.M.A. Blijlevens, M Fliedner, A
Margulies, L SharpTitle: Guidelines for the assessment of oral mucositis in adult
chemotherapy, radiotherapy and haematopoietic stem cell transplant patients Source: Eur
J Cancer. 2007 doi: 10.1016 / j.ejca. 2007. 09. 014
2.3.3.30. Author(s): MC Guedes; R Weber; MVS Gomez; RB Neto; CG Peralta; RF
Bento Title: Influence of evoked compound action potential on speech perception in
cochlear implant users Source: Rev. Bras. Otorrinolaringol. vol.73 no.4 São
Paulo July/Aug. 2007
2.3.3.31. Author(s): AP Chaves; JAP Gomes; ALH Lima Title: Ocular changes induced
by chemotherapy Source: Arq Bras Oftalmol. 2007;70(4):718-25
2.3.3.32. Author(s): Debra J Harris Title: Cancer treatment-induced mucositis pain:
strategies for assessment and management Source: Dove Medical Press, Sepp 2006, Vol
2, Iss 3, Page 251-258
2.3.3.33. Author(s): J. M. Blazeby , C. Metcalfe , J. Nicklin , C. P. Barham , J. Donovan,
D. Alderson Title: Association between quality of life scores and short-term outcome
after surgery for cancer of the oesophagus or gastric cardia Source: British Journal of
Surgery , 2005 Volume 92, Issue 12 , Pages 1502 – 1507
2.3.3.34. Author(s): Y. Dan, J. So, K. Yeoh Title: Endoscopic Screening for Gastric
Cancer. Source: Clinical Gastroenterology and Hepatology, Volume 4, Issue 6, Pages
709-716
2.3.3.35. Author(s): Bonnetain F, Bouche O, Conroy T, Arveux P, Raoul JL, Giovanni
M, Etienne PL, Mitry E, Seitz JF, Rougier P, Gırault C, Bedenne L, Title: Longitudinal
quality of life study in patients with metastatic gastric cancer. Source: Gastroenterol Clin
Biol 2005;29:1113-1124
15
2.3.3.36. Author(s): Scurtu R, Groza N, Otel O, Goia A, Funariu G Title: Quality of Life
in Patients with Esophagojejunal Anastomosis after total Gastrectomy for Cancer. Source:
Rom J Gastroenterol 2005, Vol 14. No 4, 367-372
2.3.3.37. Author(s): Sadighi S, Hohagheghi MA, Montazeri A, Sadighi Z Title: Quality
of life in patients with advanced gastric cancer: a randomizad trial comparing Docetaxel
Cisplatin 5-FU (TCF) with Epirubicin Cisplatin 5-FU (ECF). Source: BMC Cancer 2006;
1471/2407/6/274
2.3.3.38. Author(s): Olivier B Title: Comment am liorer le pronostic du cancer gastrique
en France? Source: Gastroenterol Clin Biol 2005;29:7-10
2.3.3.39. Author(s): P. Costa, J. Carraca, A. Sofia Brito, N. Figueiredo, P. Lages Title:
Avaliação multifactorial da qualidade de vida em doentes gastrectomizados por cancro
gástrico. estudo piloto de métodos de avaliação Source: J Port Gastrenterol 2006, 13:174180
2.3.3.40. Author(s): Satoshi M, Adrian AK, Akira T, Yasuhiro K, Takanori M, Junichi S
Title: Assessment and data analysis of health-related quality of life in clinical trials for
gastric cancer treatments Source: Gastric Cancer 2006, Vol 9, No 4, 254-261
2.3.3.41. Author(s): T Conroy, F Marchal, JM. Blazeby Title: Quality of Life in Patients
with Oesophageal and Gastric Cancer: An Overview Source: Oncology 2006;70:391-402,
2.3.3.42. Author(s): CC Huang , HH Lien , YC Sung , HT Liu , WC Chie Title: Quality of
life of patients with gastric cancer in Taiwan: validation and clinical application of the
Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-STO22 Source:
Psycho-Oncology, Volume 16, Issue 10 , Pages 945 – 949
2.3.3.43. Author(s): JM Bae, S Kim, YW Kim, KW Ryu, JH Lee, JH Noh, TS Sohn,
SK Hong, SM Park, CH You, JH Kim, MK Lee, YH Yun Title: Health-related quality of
life among disease-free stomach cancer survivors in Korea Source: Quality of Life
Research, 2006, Vol 15 No: 10 / 1587-1596
2.3.3.44. Author(s): P. Lagergren, P. Fayers, T. Conroy, H. Stein, O. Sezer, R. Hardwick,
E. Hammerlid, A. Bottomley, E. Van Cutsem, J. Blazeby Title: Clinical and psychometric
validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related
quality of life in patients with cancer of the oesophagus, the oesophago–gastric junction
and the stomach. Source: European Journal of Cancer, Volume 43, Issue 14, Pages 20662073
2.3.3.45. Author(s): Y. Yun, S. Kim, K. Lee, S. Park, Y. Kim Title: Age, sex, and
comorbidities were considered in comparing reference data for health-related quality of
life in the general and cancer populations Source: Journal of Clinical
Epidemiology, Volume 60, Issue 11, Pages 1164-1175
2.3.3.46. Author(s): R Pai, C Lin, T Tran, A Tarnawski Title: Leptin activates STAT and
ERK2 pathways and induces gastric cancer cell proliferation Source: Biochemical and
Biophysical Research Communications 2005, Vol 331, Iss 4, 17, Pages 984-992
16
2.3.3.47. Author(s): I Wolf, S Sadetzki, H Kanety, Y Kundel, C Pariente, N Epstein, B
Oberman, R Catane, B Kaufman, I Shimon, Title: Adiponectin, ghrelin, and leptin in
cancer cachexia in breast and colon cancer patients Source: Cancer, 2006, Vol 106, Iss 4,
Pages 966-973
2.3.3.48. Author(s): Dai Shida, Joji Kitayama, Ken Mori, Toshiaki Watanabe and
Hirokazu Nagawa Title: Transactivation of Epidermal Growth Factor Receptor Is
Involved in Leptin-Induced Activation of Janus-Activated Kinase 2 and Extracellular
Signal–Regulated Kinase 1/2 in Human Gastric Cancer Cells Source: Cancer Research
65, 9159-9163, October 15, 2005
2.3.3.49. Author(s): M Koda, M Sulkowska, LK Koda, E Surmacz, S Sulkowski, Title:
Overexpression of the obesity hormone leptin in human colorectal cancer Source: Journal
of Clinical Pathology 2007;60:902-906
2.3.3.50. Author(s): ER Ropelle, JR Pauli, KG Zecchin, M Ueno, CT Souza, J Morari,
MC Faria, LA Velloso, MJA Saad, JBC Carvalheire Title: A Central Role For Neuronal
Amp Actıvated Proteın Kınase (Ampk) In Cancer-Induced Anorexıa
Source:
Endocrinology 2007, Vol. 148, No. 11 5220-5229
2.3.3.51. Author(s): Douglas A Corley Title: Obesity and the rising incidence of
oesophageal and gastric adenocarcinoma Source: Gut 2007;56:1493-1494
2.3.3.52. Author(s): M Koda, M Sulkowska, L Kanczuga-Koda, S Cascio, G Colucci, A
Russo, E Surmacz, S Sulkowski Title: Expression of the obesity hormone leptin and its
receptor correlates with hypoxia-inducible factor-1 in human colorectal cancer Source:
Annals of Oncology 2007 18(Supplement 6):vi116-vi119
2.3.3.53. Author(s): Petersen SL; Wagner A; Gimsing P. Title: Cerebral and meningeal
multiple myeloma after autologous stem cell transplantation. A case report and review of
the literature. Source: AMERICAN JOURNAL OF HEMATOLOGY 1999, Vol 62, Iss 4,
pp 228-233.
2.3.3.54. Author(s): Wellwood J; Taylor K; Wright S; Bentley M; Hill G; Phan H; Norris
D; Livsey R. Title: Relapsed plasma cell leukaemia presenting with aggressive
extramedullary plasmacytomas in the meninges and testis - A missed opportunity for
induction CNS prophylaxis. Source: LEUKEMIA & LYMPHOMA 2002, Vol 43, Iss 4,
pp 893-896
2.3.3.55. Author(s): Hayes-Lattin B; Blanke CD; Deloughery TG. Title: Pulmonary and
intracerebral plasmacytomas in a patient without multiple myeloma: A case report.
Source: AMERICAN JOURNAL OF HEMATOLOGY 2003, Vol 73, Iss 2, pp 131-134
2.3.3.56. Author(s): C Pontikoglou; C Fragos; E Kolyvaki; G Samonis a; GD Eliopoulos;
HA.Papadaki. Title: Multiple myeloma involving the central nervous system: a report of
two cases with unusual manifestations Source: Leukemia and Lymphoma, Volume 46,
Issue 5 May 2005 , pages 737 – 741
17
2.3.3.57. Author(s): JT Rosal, I Aleman, J Ronquillo, I Puerto, L Rodriguez Title:
Glioblastoma multiforme arising in the setting of multiple myeloma Source: Haema
2005; 8(4):704-706
2.3.3.58. Author(s): Asherson RA; Cervera R. Title: Antiphospholipid antibodies and
infections. Source: ANNALS OF THE RHEUMATIC DISEASES 2003, Vol 62, Iss 5, pp
388-393
2.3.3.59. Author(s): Cervera R; Asherson RA; Acevedo ML; Gomez-Puerta JA; Espinosa
G; de la Red G; Gil V; Ramos-Casals M; Garcia-Carrasco M; Ingelmo M; Font J. Title:
Antiphospholipid syndrome associated with infections: clinical and microbiological
characteristics of 100 patients. Source: ANNALS OF THE RHEUMATIC DISEASES
2004, Vol 63, Iss 10, pp 1312-1317.
2.3.3.60. Author(s): Ramos-Casals M; Cervera R; Lagrutta M; Medina F; GarciaCarrasco M; de la Red G; Bove A; Ingelmo M; Font J. Title: Clinical features related to
antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV
infection): Description of 82 cases. Source: CLINICAL INFECTIOUS DISEASES 2004,
Vol 38, Iss 7, pp 1009-1016
2.3.3.61. Author(s): Asherson RA; Shoenfeld Y. Title: Human immunodeficiency virus
infection, antiphospholipid antibodies, and the antiphospholipid syndrome. Source:
JOURNAL OF RHEUMATOLOGY 2003, Vol 30, Iss 2, pp 214-219
2.3.3.62. Author(s): P Hopwood Title: Psychosocial aspects of risk communication and
mutation testing in familial breast-ovarian cancer Source: Current Opinion in Oncology.
July 2005, 17(4):340-344,
2.3.3.63. Author(s): A MacArthur, CD Bajdik, JJ Spinelli, C Kim-Sing, RP Gallagher
Title: Predicting interest in genetic counseling and testing for cancer susceptibility: The
British Columbia Family Cancer Survey Pilot Study Source: BC Medical Journal
Volume 48, Number 5, June 2006, page 222-225
2.3.3.64. Author(s): U. Gallkowski, H Muller, S. Manekeller, J. Boese-Landgraf, S.
Ridwelski Title: Umgang und Pflege implantierter Portkathetern bei Tumorpatiaenten –
ein interdisziplinres Problem Source: Surgical Oncology
2.3.3.65. Author(s): ÖU Yesilbalkan Title: Onkoloji Hastalarında Sık Kullanılan Venöz
Giriş Aracı: İmplante Port Kateter Source: C.Ü. Hemşirelik Yüksek Okulu Dergisi 2005,
9 (2)
2.3.3.66. Author(s): KW Jauch, W Schregel, Z Stanga Title: 9 Technik und Probleme der
Zugange in der parenteralen Ernahrung Source: Aktuel Ernaehr Med 2007; 32,
Supplement 1: S41-S53
2.3.3.67. Author(s): N. Villanueva; E. Esteban; I. Muñiz J. VieitezI L. Olay; I. Jimenez;
P. Jimenez; M. Luque; B. Llorente; M. Capelan; E. Estrada; Y. Fernández; J. Fra; A. J.
Lacave Title: Radioterapia torácica con 70 Gy concurrente con docetaxel o paclitaxel
semanal tras quimioterapia de inducción en pacientes con carcinoma de pulmón no
18
microcítico localmente avanzado. Estudio prospectivo de tolerancia y eficacia Source:
Oncología (Barc.) v.29 n.10 Madrid dic. 2006
2.3.3.68. Author(s): EE Vokes, J. E. Herndon, M. J. Kelley, D. Watson, M. G. Cicchetti,
M. R. Gren Title: Induction chemotherapy followed by concomitant chemoradiotherapy
(CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung
cancer (NSCLC): Initial analysis of a randomized phase III trial Source: Journal of
Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol
22, No 14S (July 15 Supplement), 2004: 7005
2.3.3.69. Author(s): YS Gouda, HM Kohail, NA Elddeb, AM Omar, MM El-Geneidy,
YM Elkerm Title: Randomized Study of Concurrent Carboplatin, Paclitaxel, and
Radiotherapy Induction Chemotherapy in Patients with Locally Advanced Non Small cell
lung cancer Source: Journal of the Egyptian Nat. Cancer Inst. March 2006, Vol 18, No 1,
73-81
2.3.3.70. Author(s): Rossi P; Di Lorenzo G; Formisano R; Buzzi MG. Title:
Subcutaneous sumatriptan induces changes in frequency pattern in cluster headache
patients. Source: HEADACHE 2004, Vol 44, Iss 7, pp 713-718
2.3.3.71. Author(s): K. Paemeleire, A. Bahra, S. Evers, MS Matharu, PJ Goadsby, Title:
Medication-overuse headache in patients with cluster headache Source: NEUROLOGY
2006;67:109-113
2.3.3.72. Author(s): S Sitalakshmi, R Karuna, D Prema Title: Do plasma D-dimer levels
correlate with disease stage in colonic carcinoma? Source: Indian Journal of Surgery,
2006, Vol 68, Iss 6, Page 306-309
2.3.3.73. Author(s): JIN Xiao-shi Title: The research on the changes of the D-dimer and
fibrinogen concentrations in the patients with colorectal carcinoma Source: Journal of
Tianjin Medical University 2006, VoI．12．No．3 Sep．404-405
2.3.3.74. Author(s): E Renoult, C Buteau, V Lamarre, N Turgeon, B Tapiero Title:
Infectious risk in pediatric organ transplant recipients: Is it increased with the new
immunosuppressive agents? Source: Pediatric Transplantation 2005, 9 (4), 470–479
2.3.3.75. Author(s): Wang HX, Jı SQ, Zhu L, Lıu J, Xue M, Dıng L, Duan LN, Yan HM,
Chen HR Title: Neurological Complications Following Haploidentical Bone Marrow
Transplantation Source: Journal of Experimental Hematology 2005, Vol 13, No 6, 11281130
2.3.3.76. Author(s): Atesci FC; Baltalarli B; Oguzhanoglu NK; Karadag F; Ozdel O;
Karagoz N. Title: Psychiatric morbidity among cancer patients and awareness of illness.
Source: SUPPORTIVE CARE IN CANCER 2004, Vol 12, Iss 3, pp 161-167
2.3.3.77. Author(s): Mehta VK, Poen J, Ford J, Oberhelman H, Vierra MA, Bastidas AJ,
Fisher GA. Title: Protracted Venous Infusion 5-Fluorouracil With Concomitant
Radiotherapy Compared With Bolus 5-Fluorouracil for Unresectable Pancreatic Cancer
Source: American Journal of Clinical Oncology. 2001, 24(2):155-159,
19
2.3.3.78. Author(s): R Wilkowski, M Wolf, V Heinemann Title: Primary Advanced
Unresectable Pancreatic Cancer Source: Pancreatic Cancer, 2007, Vol 177, Iss 80-15,
Pages 79-93
2.3.3.79. Author(s): S Höcht, T Wiegel, A Siegmann, W Hinkelbein Title:
Radiochemotherapy in Unresectable Pancreatic Cancer
Source: Front Radiat Ther
Oncol. 2004, Vol 38, pp 87-93.
2.3.3.80. Author(s): GJ Chang, MAR Bigas, JM Skibber, VA Moyer Title: Lymph Node
Evaluation and Survival After Curative Resection of Colon Cancer: Systematic Review
Source: Journal of the National Cancer Institute 2007 99(6):433-441
2.33.81. Author(s): P Greco, S Andreola, G Magro, F Belli, G Giannone, GF Gallino,
E Leo Title: Potential pathological understaging of pT3 rectal cancer with less than 26
lymph nodes recovered: a prospective study based on a resampling of 50 rectal specimens
Source: Virchows Archiv, 2006, Vol 449, No 6, Page 647-651
2.3.3.82. Author(s): Caronna R; Cardi M; Sammartino P; Mangioni S; Pittau G;
Scozzafava S; Catinelli S; Chirletti P; Stipa V. Title: Functional results of a personal
technique of reconstruction after pancreaticoduodenectomy. Source: JOURNAL OF
EXPERIMENTAL & CLINICAL CANCER RESEARCH 2003, Vol 22, Iss 4, pp 187189
2.3.3.83. Author(s): JK Aronson Title: A worldwide yearly survey of new data and
trends Source: Elsevier, Side Effects of Drugs Annual 26,
2.3.3.84. Author(s): J Shuster Title: ISMP Adverse Drug Reactions Reports Source:
Hospital Pharmacy, 2002, Volume 37, Number 3, pp 242–249, 333
2.3.3.85. Author(s): LCS Martinez, NEC Ceballos, EM Carrillo Title: To know the
survival in patients with renal cell carcinoma Source: Collegio Mexicano de Urologia,
2002, Vol 17, No 4, pp 187-192
2.3.3.86. Author(s): DE Rapp, WS Reynolds, A Lucioni, GT Bales Title: Surgical
technique using AdVance™ Sling placement in the treatment of post-prostatectomy
urinary Incontinence Source: International Braz J Urol. 2007, Vol. 33 (2): 231-237,
2.3.3.87. Author(s): G Barbagli, M Lazeri Title: Surgical technique using AdVance™
Sling placement in the treatment of post-prostatectomy urinary Incontinence Source:
International Braz J Urol. 2007, Vol. 33 (4): 461-469
2.3.3.88. Author(s): S Suryanarayanan Title: Desıgn, development, and characterızatıon
of a prototype dıgıtal mammography system Source: Georgia Institute of Technology,
2006
2.3.3.89. Author(s): Garsten J. Title: The Yale-Affiliated gastroenterology program Personal note. Source: JOURNAL OF CLINICAL GASTROENTEROLOGY 1996, Vol
22, Iss 4, pp 255-260.
20
2.3.3.90. Author(s): Lier H; Thees C; Nadstawek J. Title: Anaesthesia and epilepsy - a
review. Source: ANASTHESIOLOGIE & INTENSIV MEDIZIN 2003, Vol 44, Iss 12, pp
857-868
2.3.3.91. Author(s): Lorenzo OA; Fernandez-Monras F; Arago JV; Abaurrea FR. Title:
Progressive systemic sclerosis and inflammatory bowel disease. Source: REVISTA
ESPANOLA DE ENFERMEDADES DIGESTIVAS 2002, Vol 94, Iss 6, pp 372-373.
2.3.3.92. Author(s): Epstein JB; Truelove EL; Oien H; Allison C; Le ND; Epstein MS.
Title: Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to
cancer or cancer therapy. Source: ORAL ONCOLOGY 2001, Vol 37, Iss 8, pp 632-637.
2.3.3.93. Author(s): Moncoucy X; Hamon R; Diebold MD; Coussinet S; Pennaforte JL;
Thiefin G; Cadiot G. Title: Systemic sclerosis and ulcerative colitis. Source:
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 2001, Vol 25, Iss 3, pp 324325
2.3.3.94. Author(s) Ulusakarya A; Youssef A; Bayle C; Vantelon JM; Munck JN. Title:
Plasma cell meningitis after an autograft in a patient with multiple myeloma. Source:
LEUKEMIA & LYMPHOMA 1999, Vol 34, Iss 5-6, pp 633-634
2.3.3.95. Author(s): Leleu X; Jouet JP; Plantier I; Zandecki M; Lai JL; Mucha D;
Lejeune JP; Bauters F; Facon T. Title: Isolated neurological relapse following stem cell
transplantation in plasma cell leukemia: a report of two cases. Source: LEUKEMIA 1999,
Vol 13, Iss 2, pp 307-309.
2.3.3.96. Mohammadine E; Benabdellah W; Lahlou MK; Benamr S; Essadel H; Belmahi
AM; Abbassi A; Ukkas A; Taghy A; Chad B; Zizi A; Belmahi A. Title: About a pseudo
neoplasic colic stenosis preceding systemic scleroderma. Source: ANNALES DE
GASTROENTEROLOGIE ET D HEPATOLOGIE 1997, Vol 33, Iss 3, pp 127-131.
2.3.3.97. Author(s): Heymann WR. Title: Advances in the cutaneous manifestations of
thyroid disease. Source: INTERNATIONAL JOURNAL OF DERMATOLOGY 1997,
Vol 36, Iss 9, pp 641-645
2.3.3.98. Author(s): Kilchenstein W; Muller OA. Title: Progressive systemic
scleroderma - Involvement of the gastrointestinal tract. Source: AKTUELLE
RHEUMATOLOGIE 1996, Vol 21, Iss 4, pp 184-189
2.3.3.99. Author(s): HEYMANN WR. Title: CUTANEOUS MANIFESTATIONS OF
THYROID-DISEASE. Source: JOURNAL OF THE AMERICAN ACADEMY OF
DERMATOLOGY 1992, Vol 26, Iss 6, pp 885-902.
2.3.3.100. Author(s): Rohwer, N. ve ark. “HIF-1alpha determines the metastatic
potential of gastric cancer cells,” Br J Cancer., 100(5):772-81 (2009).
2.3.3.101. Author(s): Casado, E. ve ark. “UFT (tegafur-uracil) in rectal cancer,” Ann
Oncol., 19(8):1371-8, Review, (2008).
21
2.3.3.102. Author(s): 1. Akil, N. ve ark., “High-risk human papillomavirus infections in
breast cancer in Syrian women and their association with Id-1 expression: a tissue
microarray study,” Br J Cancer, 5;99(3):404-7 (2008)
2.3.3.103. Author(s): Liang, W. Ve ark., “Hypothetic association between human
papillomavirus infection and breast carcinoma,” Med Hypotheses., 70(2):305-7 (2008).
2.3.3.104 Author(s): Cazzaniga, M. ve ark., “Analysis of the presence of cutaneous and
mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its
role in breast carcinogenesis,” Breast Cancer Res Treat., 114(3):599-605 (2009).
2.3.3.105. Author(s):
Mendizabal-Ruiz, A.P. ve ark., “Low frequency of human
papillomavirus DNA in breast cancer tissue,” Breast Cancer Res Treat., 114(1):189-94
(2009).
2.3.3.106. Author(s): Amarante, M.K. ve ark., “The possible involvement of virus in
breast cancer,” J Cancer Res Clin Oncol., 135(3):329-37 (2009).
2.3.3.107. Author(s): Sun, L. Ve ark., “In GFP with high risk HPV-18E6 fusion protein
expressed 293T and MCF-7 cells, the endogenous wild-type p53 could be transiently
phosphorylated at multiple sites,” J Exp Clin Cancer Res., 27:35 (2008).
2.3.3.108. Author(s): He, Q. Ve ark., “The correlations between HPV16 infection and
expressions of c-erbB-2 and bcl-2 in breast carcinoma,” Mol Biol Rep., 36(4): 807-12
(2009).
2.3.3.109. Author(s): Koppie, T.M. ve ark., “Standardization of pelvic lymphadenectomy
performed at radical cystectomy: can we establish a minimum number of lymph nodes
that should be removed?,” Cancer., 107(10):2368-74 (2006).
2.3.3.110. Author(s): Govindarajan, A. ve ark., “Lymph node evaluation in early-stage
colon cancer,” Clin Colorectal Cancer., 7(4):240-6 (2008).
2.3.3.111. Author(s): York Health Economics c o n s o r t ı u m, Department Of Health,
Bowel Cancer Services: Costs and Benefits Literature Review, York Health, April 2007
2.3.3.112. Author(s): Tzanopoulou, S. ve ark. “Synthesis, characterization, and
biological evaluation of M(I)(CO)(3)(NNO) complexes (M = Re, Tc-99m) conjugated to
2-(4-aminophenyl) benzothiazole as potential breast cancer radiopharmaceuticals”,
Journal Of Medicinal Chemistry, 49, 5408-5410 (2006).
2.3.3.113. Author(s): Richardson, G. ve ark. “Chemotherapy induced diarrhea,” J Oncol
Pharm Pract., 13(4):181-98. Review (2007).
22
International Abstracts:
2.4.1.1. Vassallo P, Pearson WN, Turhal N. The diagnostic role of transesophageal echo (TEE) in
patients with pulmonary emboli but no obvious embolic source. Chest, 1993, 104:2, 141S.
2.4.1.2. Terk M, Turhal N, Mandeli J, et al: Long-term follow-up of combined modality therapy
for unresectable pancreatic cancer. Proceedings of American Society of Clinical Oncology 1996,
16, 307a.
Atıflar: 3 Adet
http://scholar.google.com.tr/scholar?hl=tr&lr=&cites=4331184910065725847
2.4.1.3. Turhal NS, Bruckner HW. Neoadjuvant treatment of gastric and gastroesophageal
cancers. Journal of Balkan Union of Oncology 1998, 3:49.
2.4.1.4. Turhal NS, Isola L, Scigliano E, Vlachos A, Fruchtman S. A study of cyclosporine A and
imipenem associated grand mal seizures in allogeneic bone marrow transplantation (BMT).
Annals of Oncology 1998 9:140.
Atıflar: 2 Adet
2.4.1.5. Erdal S, Karacay S, Turhal NS. Symptomatic Treatment of Chemotherapy Induced
Mucositis. Anti-Cancer Treatment 1999 9:259.
2.4.1.6. Turhal NS, Ekenel M, Ozgan A, Bekiroglu N. Attitude Toward Genetic Testing for
Cancer Risk Assessment in Turkish Society. European Journal of Gynecological Oncology 1999
20(Supp): 121-122.
2.4.1.7. Turhal NS, Kabakas F, Atalay G, Karamanoglu A. Outpatient Cancer Care in a Turkish
University Hospital. Proceedings of American Society of Clinical Oncology 1999, 1652.
B. DOÇENTLİK SONRASI
2.4.1.8. Salepci T, Turhal NS. Cisplatin and etoposide in extra pulmonary small cell cancer.
Proceedings of American Society of Clinical Oncology 2043, 2000.
2.4.1.9. Turhal NS, Gurses I, Akbaba P. Neoplastic disease prevalence during 1998-99 in
Marmara University hospital in Istanbul Turkey. Proceedings of American Society of Clinical
Oncology 1773, 2000
2.4.1.10. Guler N, Yucel I, Ozet A, Bilkay BC, Erkisi M, Onur H, Buyukunal E, Turhal S, Firat
D. Vinorelbine, Epirubicin and 5 FU combination in the first line treatment of metastatic breast
carcinoma. Annals of Oncology 2000 11(4): 137.
23
2.4.1.11. Abacıoglu U, Sengoz M, Atasoy B, Turhal S. A pilot study of low dose weekly
gemcitabine and concurrent radiation in patients with locally advanced pancreatic cancer. The
third annual global oncology young investigators´ meeting. 2001.
2.4.1.12. Sengoz M, Caglar H, Abacıoglu U, Atasoy B, Turhal S, Gulluoglu B. Patient
characteristics and treatment results of postoperatively irradiated breast cancer patients. The Breast
Journal 2001 7(5): 42.
2.4.1.13. Atalay G, Gumus M, Aliustaoglu M, Turhal NS. The method of detection and its
relationship with the disease stage in Turkish breast cancer patients. The Breast Journal 2001 7(5):
47
2.4.1.14. Dincbas FO, Koca S, Altınel A, Hancılar T, Cavusoglu M, Turhal S, Uskent N,
Ozguroglu M, Okkan S. Continuous accelerated hyperfractionated radiotherapy (CHART) plus
chemotherapy (CT) with vinorelbine (VB) and cisplatinum (CDDP) in locally advanced NSCLC
(TOG-011 study). European Journal of Cancer 2001 37(6): S53
2.4.1.15. Gumus M, Atalay G, Aliustaoglu M, Guler S, Ekenel M, Karamanoglu A, Turhal NS.
Attitude toward genetic testing in Turkish society. European Journal of Cancer 2001 37(6): S237.
2.4.1.16. Gumus M, Atalay G, Aliustaoglu M, Karamanoglu A, Turhal NS. Outcome of patients
after adjuvant treatment in stage B2/C colon cancer in Istanbul. Twelfth International Congress on
Anti-Cancer Treatment. Proceeding Book, February 2002: 150.
2.4.1.17. Aliustaoglu M, Gumus M, Atalay G, Sengoz M, Abacıoğlu U, Karamanoglu A, Turhal
NS. The survival characteristics of the stage IIIB and IV non small cell lung cancer patients in
Marmara University Hospital in Istanbul, Turkey. Twelfth International Congress on Anti-Cancer
Treatment. Proceeding Book, February 2002: 124.
2.4.1.18. Atalay G, Gumus M, Aliustaoglu M, Turhal NS. Predictive factors associated with
axillary lymph node metastasis (ALNM) in T1, T2 and T3 breast carcinomas. European Journal of
Cancer 2002 38(3): S115.
2.4.1.19. Karamanoglu A, Yumuk PF, Gumus M, Aliustaoglu M, Selimen D, Sengoz M, Turhal
NS. Port needles need not be removed as frequently in infusional cancer chemotherapy, our
experience in a university hospital in Istanbul, Turkey. Bone Marrow Transplantation 2002 29(2):
S275.
2.4.1.20. Gumus M, Aliustaoglu M, Atalay G, Dane F, Caglar H, Sengoz M, Turhal NS. The
extension of nodal sampling in colorectal cancer patients in Marmara University Hospital,
Istanbul. Proceedings of ASCO Volume 21, 2002: 133b.
2.4.1.21. Turhal NS, Efe B, Gumus M, Aliustaoglu M, Karamanoglu A, Sengoz M. Patient
satisfaction in Marmara University outpatient chemotherapy unit in Istanbul. Proceedings of
ASCO Volume 21, 2002: 252b.
Atıflar: 1 Adet
2.4.1.22. Aliustaoglu M, Atalay G, Gumus M, Turhal NS. Outcome of adjuvant treatment in
elderly Turkish breast cancer patients. Proceedings of ASCO Volume 21, 2002: 259b.
2.4.1.23. Dane F, Turhal NS, Gumus M, Dede F, Cakaloglu F, Savci D, Gulluoglu B, Kayahan
24
M, Turoglu T. 99m-Tc-MDP scintimammography to assess angiogenesis in patients with
untreated breast cancer. Proceedings of ASCO Volume 21, 2002: 291b.
2.4.1.24. Aliustaoglu M, Yumuk F, Gumus M, Ekenel M, Bolukbas F, Bolukbas C, Atalay G,
Mutlu N, Turhal NS. Plasma D-dimer levels in patients with benign and malignant gastric lesions.
Annals of Oncology 2002 Vol 13 (Supp 5): 190.
2.4.1.25. Atalay G, Gumus M, Aliustaoglu M, Abacıoglu U, Sengoz M, Gulluoglu B, Turhal NS.
Outcome of Turkish breast cancer patients who received epirubicin based adjuvant chemotherapy.
Annals of Oncology 2002 Vol 13 (Supp 5):44.
2.4.1.26. Ekenel M, Atalay G, Gumus M, Yumuk F, Aliustaoglu M, Karamanoglu A, Turhal NS.
Incidence of chemotherapy induced amenorrhea in premenopausal Turkish breast cancer patients.
Fourteenth International Congress on Anti-Cancer Treatment Proceeding Book, February 2003:
159.
2.4.1.27. Ekenel M, Atalay G, Gumus M, Yumuk F, Aliustaoglu M, Karamanoglu A, Turhal NS.
Outcome of breast cancer patients after adjuvant therapy in Istanbul, Turkey. Fourteenth
International Congress on Anti-Cancer Treatment Proceeding Book, February 2003: 160
2.4.1.28. Aydin SZ, Yumuk PF, Ekenel M, Gumus M, Aliustaoglu M, Karamanoglu A, Sengoz M,
Turhal NS. The absence of irinotecan associated acute diarrhea with atropine premedication.
Proceeding Book, 205-206, 14th International Congress on Anti-Cancer Treatment, Paris, France,
1-4 February, 2003.
2.4.1.29. Turhal NS, Gumus M, Ekenel M, Guzet E, Yumuk F, Avery B. Prognostic factors and
treatment outcomes of adjuvant breast cancer patients in two locations: Tennessee USA and
Istanbul Turkey. Proceedings of ASCO Volume 22, 2003: 556.
2.4.1.30. Komurcu S, Turhal NS, Altundag K, Atahan L, Savas-Turna H, Manavoglu O, Yavuz
AA, Ozkok S, Aliustaoglu M, Altınbas M, Pak Y, Cooper R, Yaylacı M, Demirkan B, Engin K,
Ozdemir F. A clinical evaluation of transdermal fentanyl in adults with cancer pain: Phase IV,
multicentre trial. Supportive Care in Cancer 2003 11(6): A39.
2.4.1.31. Aliustaoglu M, Gumus M, Yumuk F, Ekenel M, Karamanoglu A, Sengoz M, Turhal NS.
The survival characteristics of the stage IIIB and IV non small cell lung cancer patients in
Marmara University hospital in Istanbul, Turkey. Lung cancer 2003 Vol 41 Supp:2 S94.
2.4.1.32. Dane F, Iyikesici S, Gumus M, Yumuk PF, Ekenel M, Atalay G, Karamanoglu A,
Turhal NS. Adjuvant treatment outcome of high risk stage II and III colon cancer patients treated
in Marmara University, Istanbul. Proceeding Book, 206-207, 15th International Congress on AntiCancer Treatment, Paris, France, 9-12 February, 2004 p247.
2.4.1.33. Gunduz F, Yumuk PF, Dane F, Peker O, Ekenel M, Iyikesici S, Atalay G, Turhal NS.
Mantle cell lymphoma presenting as a breast mass. Proceeding Book, 206-207, 15th International
Congress on Anti-Cancer Treatment, Paris, France, 9-12 February, 2004 p211.
2.4.1.34. Dane F, Yumuk PF, Turhal NS, Ekenel M, Basaran G, İyikesici S, Tecimer C. Folfox4
in metastatic colorectal cancer (MRC) patients who progressed after infusional 5FU/Irinotecan
based combination regimens. Proceedings ASCO Volume 23, 2004:3729.
2.4.1.35. Aliustaoğlu M, Gumus M, Midi A, Celikel C. A, Ekenel M, Yumuk PF, Basaran G,
Turhal NS. Prognostic value of thymidylate synthase and cox-2 expression in colorectal cancer
patients tumors. Proceedings ASCO Volume 23, 2004:3731
25
2.4.1.36. Cabuk D, Yumuk PF, Abacioglu U, Demir G, Dane F, Gumus M, Ozguroglu M, Ekenel
M, Basaran G, Turhal NS. Is the incidence of anal cancers different in Moslem societies.
Proceedings ASCO Volume 23, 2004:4233
2.4.1.37. Abacioglu U, Yumuk PF, Caglar H, Sengoz M, Turhal NS. Results of concurrent
chemoradiotherapy (CRT) with low dose weekly gemcitebine (G) in stage III non-small cell lung
lung cancer (NSCLC). Proceedings ASCO Volume 23, 2004:7318
2.4.1.38. Yumuk PF, Turhal NS, Gumus M, Hatabay NF, Turken O, Ozkan A, T. Selepci,
Aliustaoglu M, Ekenel M, Ahiskali R. Paclitaxel (P) (day 1 and 8) and carboplatin (C) given on
every 3 weeks in advanced (stage III-IV) non-small cell lung cancer (NSCLC). Proceedings
ASCO Volume 23, 2004:7321
2.4.1.39. Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Ekenel M, Basaran G, Dane F, Kaya
H, Barisik N, Turhal NS; Human papilloma virus: Is it a new etiological factor in breast cancer?.
2.4.1.40. Turhal NS, Popov I. Colorectal cancer care in Balkans. Procedings of Balkan Union of
Oncology Educational Book 2004 C-109
2.4.1.41. Basaran GA, Ekenel M, Demirkalem P, Cakır T, Gulluoglu B, Gumus M, Dane F,
İyikesici S, Yumuk F, Turhal S. Clinical outcome of breast cancer patients with pT1N0M0
disease. Annals of Oncology 2004 15(3):257P, iii68.
2.4.1.42. Dane F, Turhal NS, İyikesici S, Gumus M, Yumuk PF, Basaran G, Ekenel M, Avery B.
Clinical features and adjuvant treatment outcomes of colon cancer in two outpatient populations of
Knoxville Tennessee and İstanbul Turkey. Annals of Oncology 2004 15(3): 355P, iii95
2.4.1.43. Iyikesici S, Turhal NS, Yumuk PF, Dane F, Gumus M, Basaran G, Ekenel M, Avery B.
Treatment outcomes in non-small cell lung cancer patients: Comparison between Marmara
University, İstanbul Turkey and Knoxville Tennessee. Annals of Oncology 2004 15(3): 741,
iii195.
PROFESÖRLÜK SONRASI
2.4.1.44. İyikesici MS, Kefeli U, Basaran G, Dane F, Ekenel M, Yumuk PF, Turhal NS, The
prognostic impact of body mass index (BMI) in early breast cancer (BC) patient (pts) Proceedings
2.4.1.45. Yumuk PF, Yumuk VD, Yazici D, Ege B, Bekiroglu N, Dane F, Iyikesici S, Basaran G,
NS Turhal, “The impact of body mass index on cancer: A Hospital-based study,” 14th European
Congress on obesity, Blackwell Publishing, Volume 6, Supplement 1, Page 82 (Abstract 256),
Athens, 2005.
2.4.1.46. Basaran G, Dane F, Iyikesici S, Ekenel M, Yumuk PF, Turhal NS, Clinical and
pathological characteristics of early breast cancer (EBC) patients <35 years old. Proceedings
2.4.1.49. Ekenel M, Basaran G, Dane F, Iyikesici S, Yumuk PF, Turhal NS, Outcome of adjuvant
treatment in elderly Turkish breast cancer patients. Proceedings ASCO Volume 23, 2005:896
26
2.4.1.47. Cabuk D, Basaran G, Yumuk PF, Celikel C, Dane F, İyikesici MS, Ekenel M, Turhal
NS, VEGF, HIF-1 alpha and CD34 expressions in gastric tumors (tms): Relationship with
pathological factors and prognostic impact on survival. Proceedings ASCO Volume 23, 2005:4040
2.4.1.48. Gumus M, Palak B, İyikesici S, Yumuk PF, Seker M, Topal A, Dane F, Salepci T, Yayla
A, Turhal NS, Outcome of elderly patients with advanced non-small cell lung cancer.
2.4.1.49. Yumuk PF, Turhal NS, Ahiskali R, Gumus M, Hatabay N, Turken O, Ozkan A, Salepci
T, Aliustaoglu M. P53 or Her2/neu as prognostic factors in advanced non-small-cell lung cancer
treated with paclitaxel. 11th World Conference on Lung Cancer, Barcelona, Spain. 3-6 July 2005.
2.4.1.50. Iyikesici MS, Yumuk PF, Dane F, Ekenel M, Basaran G, Turhal NS, Outcome of
patients with stage III and IV non-small cell lung cancer in Marmara University Hospital. 11 th
World Conference on Lung Cancer, Elsevier, Volume 49 Supp 2, S249, Barcelona, Spain. 3-6 July
2005.
2.4.1.51. İyikesici M, Yumuk PF, Dane F, Ekenel M, Basaran G, Turhal NS, Outcome of patients
with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey.
Abstract of the 11 th World Conference on Lung Cancer, Elsevier Volume 49 Supp 2, 2005: S249
2.4.1.52. Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Akgun Z, Ozden S, Mayadagli
A, Turhal NS, Sengoz M. Tolerability assessment of urasil-tegafur (UFT)/folinic acid (FA) as
concurrent chemoradiation (CRT) in adjuvant rectal cancer treatment. Marmara University School
of Medicine, Istanbul, Turkey; Lutfi Kirdar Kartal State Hospital, Istanbul, Turkey. Proceedings
ASCO Volume 24 2006:13559
2.4.1.53. Dane F, Gumus M, Iyikesici MS, Yumuk PF, Basaran G, Atasoy BM, Abacioglu U,
Cabuk D, Teomete M, Turhal NS, Outcome of rectal carcinoma patients receiving adjuvant
chemoradiotherapy in Marmara University Hospital, Istanbul, Turkey. Proceedings ASCO
Volume 24 2006:13584
2.4.1.54. Yalcin B, Aydin F, Zengin N, Ilhan M, Isikdogan A, Aykan F, Demir G, Celik I, Turhal
NS, Icli F, Akbulut H. The clinicopathological and socioeconomic features of patients with gastric
cancer in Turkey (Turkish Oncology Group) Ankara University School of Medicine, Ankara
Turkey; Karadeniz Teknik University School of Medicine, Trabzon, Turkey; Ankara Numune
Hospital, Ankara, Turkey; Yuzuncu Yil University School of Medicine, Van, Turkey; Dicle
University School of Medicine, Diyarbakir, Turkey; Istanbul University, Oncology Institute,
Istanbul, Turkey; Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Hacettepe
University Oncology Hospital, Ankara Turkey; Marmara University School of Medicine, Istanbul,
Turkey. Proceedings ASCO Volume 24 2006: 20098
2.4.1.55. Kefeli U, Karamanoglu A, Dane F, Yumuk PF, Iyikesici MS, Basaran G, Turhal NS.
Prolonged interval in Prophylactic Heparin Flushing for Maintenance Subcutaneous Implanted
Port Care in Patients with Cancer. 17th International Congress on Anti-Cancer Treatment, Abstract
Book Page 348, 30th January-2nd February 2006, Paris, France
2.4.1.56. Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk FP, Akgun Z, Ozden S, Mayadagli
A, Turhal NS, M Sengoz, “Concurrent administration of urasil-tegafur and folinic acid with
radiation for locally advanced rectum cancer: tolerability and quality of life assessments,” 25th
ESTRO Annual Meeting, Leipzig, Radiother Oncol., Vol. 81 (Suppl. 1), S234, Elsevier, Ireland,
2006.
27
2.4.1.57. Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Akgun Z, Ozden S, Mayadagli
A, Turhal NS, Sengoz M. Concomitant administration of uracil-tegafur (UFT) and folinic acid
(FA) during inradiation for locally advanced rectal cancer: tolerability assessment. 6 th Congress
Balkan Union of Oncology, 13-16 September 2006, Sofia, Bulgaria, 58:OP80,
2.4.1.58. Dane F, Gumus M, Iyikesici S, Basaran G, Ozturk A, Atasoy BM, Abacioglu U, Cabuk
D, Teomete M, Turhal NS, Division of Medical Oncology, Marmara University Hospital,
Istanbul, Turkey. Outcome of rectal carcinoma patients receiving adjuvant chemoradiotherapy. 6 th
Congress Balkan Union of Oncology, 13-16 September 2006, Sofia, Bulgaria, 61:PP93.
2.4.1.59. Dane F, Yumuk PF, Gumus M, Iyikesici S, Tufan A, Basaran G, Cabuk D, Ozturk A,
Erdem R, Teomete M, Turhal NS, Dept. Of Internal Medicine Division of Oncology, Marmara
University Hospital, Istanbul, Turkey. Outcome of unresectable locally advanced and/or metastatic
colorectal cancer patients receiving systemic chemotherapy. 6 th Congress Balkan Union of
Oncology, 13-16 September 2006, Sofia, Bulgaria, 64:PP107.
2.4.1.60. Turhal NS, Dept. Of Internal Medicine Division of Oncology, Marmara University
Hospital, Istanbul, Turkey. Integration of Balkan Oncology in International Study Groups: the
University of Marmara Experience. 6th Congress Balkan Union of Oncology, 13-16 September
2006, Sofia, Bulgaria, 109:OP251.
2.4.1.61. Cabuk D, Basaran G, Iyikesici S, Ekenel M, Dane F, Teomete M, Gumus M, Aliustaoglu
M, Yumuk PF, Turhal NS, Marmara University Hospital, Medical Oncology, Istanbul, Turkey.
Outcome of adjuvant treatment in Turkish Breast Cancer (BC) patients (PTS): single institution
experience. Annals of Oncology Abstract Book of the 31 st ESMO Congress 29 September – 3
October 2006, Istanbul, Turkey. Volume 17, Supp, 9/302
2.4.1.62. Yumuk PF, Gumus M, Kaya H, Alam K, Dane F, Gulluoglu B, Salepci T, Barisik N,
Basaran G, Turhal NS. Association Between Presence of HPV DNA and P53 in Breast Cancer
Patients. Annals of Oncology Abstract Book of the 31 st ESMO Congress 29 September – 3
2.4.1.63. Basaran G, Cabuk D, Caglar H, Iyikesici S, Tebessum C, Gulluoglu B, Kaya H, Dane F,
Yumuk PF, Turhal NS. Stage I (T1N0M0) Breast Cancer (BC): Pathological Characteristics and
Clinical Outcome. Annals of Oncology Abstract Book of the 31 st ESMO Congress 29 September –
3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/321
2.4.1.64. Dane F, Yumuk PF, Gumus M, Iyikesici S, Tufan A, Basaran G, Cabuk D, Teomete M,
Turhal NS, Marmara University Hospital Department of Oncology Istanbul, Turkey. Outcome of
metastatic colorectal cancer patients receiving palliative chemotherapy in Marmara University
Hospital. Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3
2.4.1.65. Dane F, Gumus M, Yumuk PF, Iyikesici S, Ozturk A, Basaran G, Caglar H, Cabuk D,
Teomete M, Turhal NS, Marmara University Hospital Department of Oncology Istanbul, Turkey.
Outcome of colon cancer patients receiving adjuvant chemotherapy in Marmara University
Hospital. Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3
October 2006, Istanbul, Turkey. Volume 17, Supp, 9/384.
2.4.1.66. Atasoy B, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Akgun Z, Ozden S, Mayadagli A,
Turhal NS, Sengoz M. Adjuvant comcomittant administration of Urasil-Tegafur (UFT) and
folinic acid (FA) during irradiation for locally advanced rectum cancer: Tolerability assessment.
Annals of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006,
Istanbul, Turkey. Volume 17, Supp, 9/401
28
2.4.1.67. Teomete M, Yumuk PF, Iyikesici S, Dane F, Basaran G, Cabuk D, Caglar H, Abacioglu
U, Turhal NS. Outcome of patients with stage III and IV non-small cell lung cancer in Marmara
University Hospital, Istanbul, Turkey. Annals of Oncology Abstract Book of the 31 st ESMO
Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/757P
2.4.1.68. Dane F, Topaloglu N, Abul Y, Yumuk PF, Turhal NS, Ceyhan B, Celikel T, Caglar H,
Basaran G, Ahiskali R. Interstitial pneumonitis associated with Docetaxel administration. Annals
of Oncology Abstract Book of the 31st ESMO Congress 29 September – 3 October 2006, Istanbul,
Turkey. Volume 17, Supp, 9/1069
2.4.1.69. Demir G, Zengin N, Yildiz O, Dogusoy G, Aykan F, Er O, Isikdogan A, Turhal NS,
Yilmaz U, Yalcin S. The role of lymph nodes on disease free survival in operated gastric cancer
(Turkish Oncology Group Study). Annals of Oncology Abstract Book of the 31 st ESMO Congress
29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/1100
2.4.1.70. Demir G, Zengin N, Yildiz O, Ozdamar S, Aykan F, Er O, Ilhan M, Turhal NS, Yilmaz
U, Yalcin S. Clinical profile of gastric cancer in Turkey: Factors effecting disease free survival
and relapse (Turkish Oncology Group Study). Annals of Oncology Abstract Book of the 31st
ESMO Congress 29 September – 3 October 2006, Istanbul, Turkey. Volume 17, Supp, 9/1139
2.4.1.71. Basaran G, Guney N, Saip P, Iyikesici S, Kaya H, Yazıcı H, Turhal NS. Serum
extracellular domain (ECD) levels, pAkt and MAKP expressions as potential markers for response
to trastuzumab base therapy in metastatic breast cancer patients: A Turkish Oncology Group
Study. Ann Oncol. 2006 Sept; 17 (Supp 9): ix69–ix92, Abstract 230, İstanbul, 2006.
2.4.1.72. Yumuk PF, Teomete M, Dane F, Cabuk D, Caglar H, Abacioglu U, Basaran G, Turhal
NS, Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University
Hospital, Istanbul, Turkey. 12 th. World Conference on Lung Cancer. Journal of Thoracic
Oncology, Volume 2, Number 8, Supplement 4, August 2007.
2.4.1.73. M. Gumus, F. Dane, S. Kaya, M. A. Ozturk, P. F. Yumuk, B. M. Atasoy, G. Basaran, T.
Salepci, M. Yaylaci, N. S. Turhal. The role of adjuvant chemoradiotherapy (CRT) in Turkish
patients with gastric carcinoma. Journal of Clinical Oncology, 2007 ASCO Annual Meeting
Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 15159.
2.4.1.74. F. Dane, M. Gumus, A. Ozturk, F. Yumuk, S. Iyikesici, G. Basaran, D.
Cabuk, M. Teomete, N. S. Turhal. Outcome of metastatic colorectal cancer patients
receiving second line chemotherapy in Marmara University Hospital. Journal of Clinical
Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20
Supplement), 2007: 14588
2.4.1.75. G. Atalay Basaran, D. Cabuk, F. Dane, M. Teomete, S. Iyikesici, E. Meltem,
B. Gulluoglu, H. Kaya, U. Abacıoglu, F. Yumuk, S. Turhal. Clinical outcome of nodenegative (NN) breast cancer (BC) patients. Journal of Clinical Oncology, 2007 ASCO Annual
Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 11102
2.4.1.76. Yumuk PF, Teomete M, Dane F, Cabuk D, Caglar H, Abacioglu U, Basaran G, Turhal
NS, Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University
Hospital, Istanbul, Turkey. 12 th. World Conference on Lung Cancer. Journal of Thoracic
Oncology, Volume 2, Number 8, Supplement 4, August 2007.
29
2.4.1.77. Basaran G, Cabuk D, Teomete M, Gulluoglu B, Kaya H, Dane F, Yumuk PF, Turhal
NS, Benefit from adjuvant anthracyclines according to hormone receptor status. Annual Meeting
ASCO 2008: 11513
2.4.1.78. Turhal NS, Ulus C, Sari S, Senturk N, Bingol D. Cancer-related knowledge in relatives
of cancer patients and general public in İstanbul, Turkey, Annual Meeting ASCO 2008: 20650
2.4.1.79. F Dane, M Gumus, MA Ozturk, D. Cabuk, MB Atasoy, PF Yumuk, G Basaran, MS
Iyikesici, M Teomete, U Abacioglu, NS Turhal. Clinical features and outcome of adjuvant
chemoradiotherapy in Turkish rectal carcinoma patients: Single institution experience. Annual
Meeting ASCO 2008: 15103
2.4.1.80. D Cabuk, G Basaran, H Kaya, B Gulluoglu, M Teomete, F Dane, PF Yumuk, NS
Turhal. Clinical outcome of triple-negative (TN) breast cancer (BC). Annual Meeting ASCO
2008: 11526
2.4.1.81. Dane F, Gumus M, Yaman E, Ozturk MA, Sevinc A, Atasoy BM, Cabuk D, Iyikesici S,
Yumuk PF, Basaran G, Abacioglu U, Teomete M, NS Turhal, “Demographical Survival and
Prognostic Features of Resected Rectal Cancer in Turkish Patients Population,” 18th World
Congress of the International Association of Surgeons, Gastroenterologists and Oncologists,
İstanbul, Hepato-gastroenterology, Vol. 55, (Suppl. 1), OP70, A28, H.G.E. Update Medical
Publishing, Greece, 2008.
2.4.1.82. Cabuk D., Basaran G, Teomete M, Dane F, Yumuk PF, Turhal NS,
“Clinical/pathological characteristics of breast cancer (BC) patients (pts) with triple-negative (TN)
tumors,” 7th Congress of Balkan Union of Oncology (BUON), Proceedings, OP–53, İzmir, 2008.
2.4.1.83. Yumuk PF, Teomete M, Dane F, Cabuk D, Basaran G, Turhal NS, ”Platinum plus
vinorelbine (VNR) on days 1 and 8 in advanced non-small cell lung Cancer: Single center
results,” 7th Congress of Balkan Union of Oncology (BUON), Proceedings, OP–72, İzmir, 2008.
2.4.1.84. Dane F, Gumus M, Ozturk A, Cabuk D, Basaran G, Turhal NS, “Demographics,
survival and prognostic features of resected colon Cancer in Turkish patients population,” 7th
Congress of Balkan Union of Oncology (BUON), Proceedings, OP–92, İzmir, 2008.
2.4.1.85. Dane F, Ozturk A, Gumus M, Yumuk F, Basaran G, Turhal NS, ”Survival and
prognostic features of stage II and III Rectal Cancer (RC) in Turkish patients population,” 7th
Congress of Balkan Union of Oncology (BUON), Proceedings, OP–93, İzmir, 2008.
2.4.1.86. Dane F, Gumus M, Cabuk D, Teomete, M, Yumuk PF, Turhal NS, “Prognostic factors
and treatment outcomes in patients with metastatic colorectal cancer (CRC),” 7th Congress of
Balkan Union of Oncology (BUON), Proceedings, OP–94, İzmir, 2008.
2.4.1.87. Civen H, Dede F, Dane F, Ustaoglu MA, Turhal NS, Turoglu H, Inanır S, “Does the
standard test parameters for C-14 urea breath test really work in partially gastrectomised patients
with gastric cancer,” Annual Congress of the European Association of Nuclear Medicine, Eur. J.
Nucl. Med., 35, S238, Münih, 2008.
2.4.1.88. Yumuk PF, Teomete M, Dane F, Cabuk D, Basaran G, Turhal NS, Impact of dose
reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer
(NSCLC). 2009 ASCO Annual Meeting, J Clin Oncol 27, 2009 (suppl; abstr e19055),
30
2.4.1.89. Turhal NS, Yurt N, Yurtseven G, Cabuk D, Teomete M, Gumus M. Weight gain after
adjuvant treatment in breast cancer patients in Istanbul, Turkey. 2009 ASCO Annual Meeting, J
Clin Oncol 27, 2009, (suppl; abstr e11620),
2.4.1.90. Abali H, Ata A, Turhal NS, Ozdogan M, Seyrek E, Erman M, Celik I. Frequency of comorbid illnesses in cancer patients in Turkey. 2009 ASCO Annual Meeting, J Clin Oncol 27,
2009, (suppl; abstr e20717),
2.4.1.91. Kefeli U, Yumuk PF, Ceyhan B, Dane F, Eroglu B, Cabuk D, Basaran G, Teomete M,
Turhal NS, Pulmonary toxicity in patients receiving docetaxel chemotherapy. 2009 ASCO Annual
Meeting, J Clin Oncol 27, 2009, (suppl; abstr e13532),
2.4.1.92. Turhal NS, Dane F, Seber S, Korkmaz T, Cabuk D, Basaran G, Yumuk F, Caglar H,
Atasoy B. “Challenges in applicability of Standard treatment for head and neck cancer patients in
Istanbul”. Euroasian Congress on Head & Neck Oncology, Minsk, Republic of Belarus, 16-19
July 2009, Becthиk POHц им. H. H. Блoина, Proceedings, 20(2), 2009: 116.
2.4.1.93. Cabuk D, Basaran G, Korkmaz T, Seber S, Dane F, Telli F, yumuk F, Turhal NS.
Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment
modalities. European Breast Cancer Conference 7, 24-30 March 2010 Barcelona. Eur J Cancer
Supplements, Vol . 8, No 3, p205, Poster 498 (2010)
2.4.94. Turhal NS, Basaran G, Yurt N, Yurtseven G, Cabuk D, Teomete M, Gumus M. Weight
Gain after Adjuvant Chemotherapy in Early Breast Cancer Patients in Istanbul Turkey. American
Society of Clinical Oncology 2010 Annual Meeting June 4-8 2010
2.4.1.95. Basaran G, Cabuk D, Korkmaz T, Kocar M, Telli F, Dane F, Yumuk F, Turhal NS.
Clinical, pathological factors predicting early relapse in hormone receptor early breast cancer.
BUON Congress 2010, Best Abstracts Presented at BUON Congress 2010,Proceedings Book,
8-11 September 2010, Sibiu, Romania. BA 28, page 13
2.4.1.96. Turhal NS, Dane F, Seber S, Korkmaz T, Yumuk F, Kanitez M, Telli F, Kocar M,
Basaran G. Tolerability of anthracyclines in Turkish breast cancer patients. BUON Congress 2010,
Proceedings Book, 8-11 September 2010, Sibiu, Romania. Oral presentation OP-32, page 14
2.4.1.97. Ozturk MA, Dane F, Karagoz S, Tural D, Demirelli F, Basaran G, Buyukunal E, Mandel
NM, Ç Erdamar S, Turna H, Seber S, Turhal NS, Serdengecti S. The prognostic value of
perineural invasion in patients with early stage colon cancer. BUON Congress 2010, Best
Abstracts Presented at BUON Congress 2010,Proceedings Book, 8-11 September 2010, Sibiu,
Romania. BA 65, page 23
2.4.1.98. Turhal NS, Kilickap S, S Yalcin, C Sezgin, D Yamac, H Akbulut, O Ozyilkan, F
Ozdemir, D Cabuk, A Sevinc. The association between sociodemographic parameters and the use
of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group
study. 2011 ASCO Annual Meeting, J Clin Oncol 29: 2011 (suppl; abstr e19598)
2.4.1.99 T. Korkmaz, S. Seber, G. Basaran, P.F. Yumuk, F. Dane, K. Okutur, M. Kanitez, M.
Kocar, F. Telli, G. Demir, Turhal NS. Prognostic significance of serum thymidine kinase activity
(TK1) level in patients with metastatic non-small cell lung cancer (NSCLC). 2011 ASCO Annual
Meeting. J Clin Oncol 29: 2011 (suppl; abstr e18010).
2.4.1.100. S. Seber, G. Basaran, T. Korkmaz, F. Telli, M. Kocar, M. Kanitez, F. Dane, P.F.
Yumuk, Turhal NS. Clinical / pathologic characteristics of diabetic patients with early breast
31
cancer (BC) and their survival outcome. 2011 ASCO Annual Meeting. J ClinOncol 29: 2011
(suppl; abstr e11019)
2.4.1.101. Turhal NS, Dane F, Butur S, Kocak M, Telli F, et al. Efforts to Validate the
Applicability of Established Chemotherapy Treatment in Turkish Cancer Patients. Pharm Anal
Acta S14. 2011. doi:10.4172/2153-2435.S14-001.
2.4.1.102. Dane F, Ozturk MA, Koçar M, Atasoy BM, Aktas B, Telli F, Kanitez M, Beşiroğlu M,
Yumuk PF, Turhal NS. Prognostic significance of combined positivity of lymphatic, vascular, and
perineural invasion (triple positive) in stage ii/iii colorectal cancer; a new paradigm worth to
investigate? ESMO 2012, Abstract: 547P
2.4.1.103. Atasoy BM, Cetin IA, Bozkurt SU, Turhal NS. Metastasis to Paranasal Sinuses and
Orbita of Breast Cancer With a Rare Metachronous Tumor of the Uterine Cervix. The Journal of
Craniofacial Surgery. Vol. 24 No. 1-e64 January 2013
32
National Meeting Abstracts:
2.4.2.1. Dincbas FO, Koca S, Altınel A, Hancılar T, Cavusoglu M, Turhal S, Uskent N,
Ozguroglu M, Okkan S. “Evre III küçük hücreli dışı akciğer kanserinde (KHDAK) aralıksız
hızlandırılmış hiperfraksiyone radyoterapi (CHART) ve kemoterapi çalışması (TOG-011
çalışması – Erken sonuçlar)” Bildiri Özetleri, XIV. Ulusal Kanser Kongresi (Uluslararası
katılımlı). SB-06 s: 62. İstanbul, 2001
2.4.2.2. Abacıoglu U, Sengoz M, Caglar H, Gumus M, Atalay G, Turhal S. “Rektum ve
sigmoid kanserlerinde adjuvan kemoradyoterapi sonuçları” Bildiri Özetleri, XIV. Ulusal
Kanser Kongresi (Uluslararası katılımlı), SB-07 s: 64. İstanbul, 2001
2.4.2.3. Guler N, Yucel I, Ozet A, Bilkay BC, Erkisi M, Onur H, Buyukunal E, Turhal S,
Firat D. “Metastatik meme kanserinin birinci basamak tedavisinde Vinorelbin Epirubisin 5Fluorourasil kombinasynu” Bildiri Özetleri, XIV. Ulusal Kanser Kongresi (Uluslararası
katılımlı). SB-09 s: 69. İstanbul, 2001
2.4.2.4. Gumus M, Atalay G, Aliustaoglu M, Karamanoglu A, Dane F, Turhal NS. “
Marmara Üniversitesi Hastanesi’nde izlenen evre II ve evre III kolon kanserli hastaların
değerlendirilmesi” Bildiri Özetleri, XIV. Ulusal Kanser Kongresi (Uluslararası katılımlı).
SB-14 s: 84. İstanbul, 2001
2.4.2.5. Gumus M, Atalay G, Aliustaoglu M, Karamanoglu A, Turhal NS. “Marmara
Üniversitesi Hastanesi’nde izlenen evre IV kolon kanserli hastaların değerlendirilmesi”
Bildiri Özetleri, XIV. Ulusal Kanser Kongresi (Uluslararası katılımlı). SB-14 s: 85. İstanbul,
2001
2.4.2.6. Aliustaoglu M, Atalay G, Gumus M, Karamanoglu A, Turhal NS. “ Marmara
Üniversitesi Hastanesi’nde izlenen evre III B-IV küçük hücreli dışı akciğer kanserli
hastaların sürvi karakteristiklerinin değerlendirilmesi” Bildiri Özetleri, XIV. Ulusal Kanser
Kongresi (Uluslararası katılımlı). PO-05 s: 187. İstanbul, 2001
2.4.2.7. Dane F, Turhal NS, Gumus M, Dede F, Sengoz M, Yumuk F, Turoglu T. Tc-99m
MDP scintimammography in the detection of breast lesions. Turkish Journal of Nuclear
Medicine Volume 11(1), 2002: 47.
2.4.2.8. Dane F, Turhal NS, Gumus M, Dede F, Cakalagaoglu F, Yumuk F, Turoglu T.
Correlation between Tc-99m MDP uptake and prognostic factors in breast cancer.
Turkish Journal of Nuclear Medicine Volume 11, 2002: 11
2.4.2.9. Komurcu S, Turhal NS, Altundag K, Atahan L, Savas-Turna H, Manavoglu O,
Yavuz AA, Ozkok S, Aliustaoglu M, Altınbas M. “A clinical evaluation of transdermal
fentanyl in adults with cancer pain: Phase IV, multicentre trial”. Program ve Bildiri Özet
Kitabı XV. Ulusal Kanser Kongresi , , P079 ref 0381 s:48. Antalya, 2003.
2.4.2.10. Aliustaoğlu, M., Turhal, S., Ekenel, M., Gümüş, M. ve Yumuk PF, “Evre IIII over
kanserinde kemoterapi sonuçlarımız”, Program ve Bildiri Özet Kitabı, XV. Ulusal Kanser
Kongresi, P290, Antalya, 2003.
2.4.2.11. Gümüş, M., Dane, F., Aliustaoğlu, M., Yumuk, P.F., Ekenel, M., Selepçi, T., Barışık,
N. ve Turhal NS, “Meme kanserli hastalarda normal ve tümoral doku örneklerinde human
papillomavirus (HPV) DNA sıklığı ve HPV tip tayini”, Kurs ve bildiri özet kitabı, VII. Ulusal
Meme Hastalıkları Kongresi, s: 44, Antalya, 2003.
33
2.4.2.12. Ekenel, M., Başaran, G., Gümüş, M., Aliustaoğlu, M., Dane F., Yumuk, P.F. ve NS
Turhal, “Premenopozal meme kanseri hastalarında kemoterapiye bağlı amenore insidansı ve
prognostic rolü”, Kurs ve Bildiri Özet Kitabı, VII. Ulusal Meme Hastalıkları Kongresi, P82,
Antalya, 2003.
2.4.2.13. Abacıoğlu, U., Odabaş, Ö.F., Tezcanlı, E., Çağlar, H., Yumuk, P.F., Şengöz, M. ve
Turhal S, “Kolorektal Kanserli Hastaların Yaşam Kalitesini Değerlendirmede EORTC
Kolorektal Kanser Modülü QLQ-CR38’in Türkçe Çevirisi ve Pilot-Test Çalışması”, Bildiri Özet
Kitabı, VI. Ulusal Radyasyon Onkolojisi Kongresi, P45, Antalya, 2004.
2.4.2.14. Çağlar, H., Abacıoğlu, U., Tezcanlı, E., Yumuk, F., Turhal, S. ve M. Şengöz,
“Lokal ileri evre pankreas kanserli hastalarda radyoterapi ve eş zamanlı gemsitabin
tedavisinin toksisite ve sağkalım sonuçları”, Bildiri Özet Kitabı, VI. Ulusal Radyasyon
Onkolojisi Kongresi, P48, Antalya, 2004.
2.4.2.15. Küçük hücreli dışı akciğer kanseri nedeniyle izlenen yaşlı hastalarda
kemoterapi. Palak B, Gümüş M, İyikesici S, Şeker M, Topal A, Yumuk F, Salepçi T, Yayla
A, Turhal NS, 1. Ulusal Torasik Onkoloji Kongresi, Antalya,Final Program ve Bildiri Özet
Kitabı, S78, Antalya, 2004.
2.4.2.16. Yumuk PF, İyikesici S, Gumus M, Aliustaoglu M, Dane F, Başaran G, Ekenel M,
Abacıoglu U, Turhal NS. “Kemoterapi verilen lokal ileri ve metastatik küçük hücreli dışı
akciğer kanseri hastalarının sağ kalım ve prognostik açıdan değerlendirilmesi” Final
Program ve Bildiri Özet Kitabı, 1. Ulusal Torasik Onkoloji Kongresi, S79 Antalya, 2004.
PROFESÖRLÜK SONRASI
2.4.2.17.Yumuk PF, Gümüş M, Dane F, Kaya H, Alam K, İyikesici MS, Güllüoğlu B,
Ekenel M, Atalay G, Turhal NS, “Meme kanseri hastalarında HPV-DNA ampfilikasyonu
ve P53 ekspresyonunun prognostik değeri” Program ve bildiri özet kitabı, XVI. Ulusal
Kanser Kongresi, Ref 873, Antalya, 2005.
2.4.2.18. Yalçın B, Aydın F, Zengin N, İlhan M, Demir G, Bozcuk H, Çelik İ, Turhal NS,
İçli F, Işıkdoğan A, “Türkiye’de mide kanserli hastaların klinik patolojik özellikleri: Çok
merkezli retrospektif çalışma (Türk Onkoloji Grubu)” Program ve bildiri özet kitabı, XVI.
Ulusal Kanser Kongresi, Ref 601, Antalya, 2005.
2.4.2.19. Akgün Z, Çetin İ, Karaüç, Çağlar H, Abacıoğlu U, Dane F, Yumuk PF, Şengöz
M, Turhal NS, “Mide adenokarsinomlarında cerrahi rezeksiyon sonrasında adjuvan
34
kemoradyoterapi sonuçlarımız” Program ve bildiri özet kitabı, XVI. Ulusal Kanser
Kongresi, Ref 708, Antalya, 2005.
2.4.2.20. Çetin İ, Akgün Z, Abacıoğlu U, Şengöz M, Yumuk PF, Turhal NS, “Lokal ileri
evre özafagus kanserli hastalarda primer kemoradyoterapi sonuçları” Program ve bildiri
özet kitabı, XVI. Ulusal Kanser Kongresi, Ref 822, Antalya, 2005.
2.4.2.21. Çetin İ, Akgün Z, Çağlar H, Tezcanlı E, Abacıoğlu U, Şengöz M, Yumuk PF,
Turhal NS, Türkeri L, “Mesane tümörlü hastaların kemoradyoterapi sonuçları” Program
ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi, Ref 806, Antalya, 2005.
2.4.2.22. İyikesici MS, Yumuk PF, Dane F, Başaran G, Ekenel M, Abacıoğlu U, Şengöz
M, Turhal NS, “Marmara Üniversitesi Hastanesindeki Evre III ve IV küçük hücreli dışı
akciğer kanserli hastaların sonuçları” Program ve bildiri özet kitabı, XVI. Ulusal Kanser
Kongresi, Ref 805, Antalya, 2005.
2.4.2.23. Turhal NS, Yumuk PF, İyikesici MS, Dane F, Başaran G, Ekenel M, Avery B,
“Knoxville, Tennessee, USA’da evre III ve IV küçük hücreli dışı akciğer kanserli hastaların
sonuçları. Program ve bildiri özet kitabı, XVI. Ulusal Kanser Kongresi, Ref 812, Antalya,
2005.
2.4.2.24. Meme kanserli hastaların metastaz yönünden tüm vücut MR incelemesi ile
değerlendirilmesi: Ön çalışma. Dane F, Güran S, İyikesici S, Atalay G, Yumuk F, Turhal
NS, 8. Ulusal Meme Hastalıkları Kongresi, İstanbul, Kongre Özet Kitabı, 21-24 Eylül
2005, P161.
2.4.2.25. Cabuk D, Basaran G, Yumuk PF, Celikel C, Dane F, Iyikesici MS, Ekenel M,
Turhal NS, “Mide kanserinde VEGF, HIF- Alfa, CD34 Ekspresyonu ve bu faktörlerin
prognostik önemi”. Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi, SB 03, Antalya,
2006.
2.4.2.26. Komurcu S, Turhal NS, Altundag K, Atahan L, Turna H, Manavoglu O, Yavuz
A, Ozkok S, “Transdermal fentanilin kanser ağrısı olan hastalarda etkinliğinin ve
güvenliğinin değerlendirilmesi: FAZ IV, TOG destek tedaviler çalışma grubu”, Program ve
Özet Kitabı. I. Tıbbi Onkoloji Kongresi, SB 21, Antalya, 2006.
35
2.4.2.27. Dane F, Yumuk PF, Iyikesici MS, Gumus M, Tufan A, Basaran G, Teomete M,
Turhal NS, “Palyatif kemoterapi alan metastatik kolorektal kanser hastalarının sağ kalım
sonuçları” Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi, SB 42, Antalya, 2006.
2.4.2.28. Dane F, Gümüş M, İyikesici S, Yumuk F, Öztürk A, Başaran G, Çabuk D,
Turhal NS, Adjuvan Kemoterapi alan Kolon Kanseri Hastalarının Sağkalım ve Prognostik
Açıdan Değerlendirilmesi. 1. Tıbbi Onkoloji Kongresi, Antalya, Bildiri Özet Kitabı, 29 Mart
- 2 Nisan 2006, P066.
2.4.2.29. Dane F, Gumus M, Iyikesici MS, Yumuk PF, Basaran G, Atasoy B, Abacioglu U,
Turhal NS, “Adjuvan kemoradyoterapi verilen evre II/III rektum kanseri hastalarının sağ
kalım ve prognostik açıdan değerlendirilmesi”, Program ve Özet Kitabı. I. Tıbbi Onkoloji
Kongresi, SB 45, Antalya, 2006.
2.4.2.30. Atasoy BM, Abacioglu U, Ozgen Z, Dane F, Yumuk PF, Mayadagli A, Turhal
NS, Sengoz M, “Rektum kanserinin adjuvan tedavisinde radyoterapiyle eş zamanlı
Tegafur-Urasil (UFT) / Folinik Asit (FA) uygulaması: Tolerabilite değerlendirmesi”
Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi, SB 46, Antalya, 2006.
2.4.2.31. Atasoy BM, Abacıoğlu U, Özgen Z, Dane F, Yumuk PF., Mayadağlı A, Turhal
NS ve M. Şengöz, “Rektum Kanserinin adjuvan tedavisinde radyoterapiyle eş zamanlı
Tegafur-Urasil (UFT)/Folinik asit (FA) uygulanması: Tolerabilite Değerlendirilmesi,” VII.
Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, S13, Fethiye, 2006.
2.4.2.32. Dane F, Gumus M, Iyikesici MS, Yumuk PF, Ozturk A, Basaran G, Cabuk D,
Turhal NS, “Adjuvan kemoterapi alan kolon kanseri hastalarının sağ kalım ve prognostik
açıdan değerlendirilmesi”, Program ve Özet Kitabı. I. Tıbbi Onkoloji Kongresi, P 066,
Antalya, 2006.
2.4.2.33. Öztürk A, Dane F, Tecimer T, Atasoy B, Çabuk D, Yumuk PF, Başaran G,
Teomete M, Turhal NS. “Onkoloji Kliniğine Refere edilen Selim Bir Lenf Adenopati
Nedeni: Kikuchi-Fujimoto Hastalığı” 4. Ulusal Tıbbi Onkoloji Kongresi Özet Kitabı” B 62,
Antalya, 5-9 Eylül 2007.
2.4.2.34. Dane F, Gumus M, Ozturk MA, Atasoy BM, Iyikesici S, Yumuk PF, Basaran G,
Abacıoglu U, Cabuk DO, Teomete M, Turhal NS. Rektum kanseri olgularanın klinik
özellikleri ve adjuvant kemoradyoterapi sonuçları: Tek merkez tecrübesi. Tıbbi Onkoloji
Kongresi Antalya. 26-30 Mart 2008.
2.4.2.35. Öztürk A, Dane F, Tecimer T, Atasoy B, Çabuk D, Yumuk PF, Başaran G,
Teomete M, Turhal NS. “Onkoloji Kliniğine Refere edilen Selim Bir Lenf Adenopati
Nedeni: Kikuchi-Fujimoto Hastalığı” 4. Ulusal Tıbbi Onkoloji Kongresi Özet Kitabı” B 62,
Antalya, 5-9 Eylül 2007.
2.4.2.36. Gümüş M, Dane F, Kaya S, Öztürk MA, Yumuk PF, Atasoy BM, Başaran G,
Salepçi T, Yaylacı M, ve Turhal NS, “Mide Kanserinin Adjuvan Tedavisinde
36
Kemoradyoterapinin Etkinliği,” 17.Ulusal Kanser Kongresi, Bildiri Özet Kitabı, Ref No: 774
Antalya, 2007.
2.4.2.37. Yamaç D, Turhal NS, Karaca B, Coşkun HŞ, Kömürcü Ş, Yavuzşen T, Dane F,
Yaman E, Nalça M, ve M. Akmansu, “Kanser Tanısını Söyleme Yöntemimizi Sorgulama,”
2.Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, SB29 (Sözlü Bildiri), Antalya, 2008.
2.4.2.38. Dane F, Gümüş M, Öztürk MA, Atasoy BM, İyikesici S, Yumuk PF, Başaran G,
Abacıoğlu U, Çabuk DÖ, Teomete, M ve Turhal NS, “Rektum Kanseri Olgularının Klinik
Özellikleri ve Adjuvan Kemoradyoterapi Sonuçları: Tek Merkez Tecrübesi,” 2.Tıbbi
Onkoloji Kongresi, Bildiri Özet Kitabı, P23, Antalya, 2008. [Poster Bildiri Ödülü]
2.4.2.39. Dane F, Gümüş M, Yaman E, Öztürk MA, Sevinç A, Atasoy BM, Çabuk D,
İyikesici S, Yumuk PF, Başaran G, Abacıoğlu U, Teomete M ve Turhal NS, “Türk
Toplumunda Rektum Kanserli Hastaların Demografik, Histopatolojik Özellikleri, Sağ
Kalım ve Prognostik Faktörler,” 5. Ulusal Tıbbi Onkoloji Kongresi, Bildiri Özet Kitabı, B42,
Antalya, 2008.
2.4.2.40. Atasoy BM, Dane F, Çağlar H, Cingi A, Abacıoğlu U, Turhal NS, Şengöz M ve
C. Yeğen, “Rezeke Edilebilir Lokal İleri Evre Rektum Kanserinde Preoperatif
Radyoterapiyle Eş Zamanlı Floropirimidin Uygulaması: Oral mi, İntravenöz mü?,” VIII.
Ulusal Radyasyon Onkolojisi Kongresi, Bildiri Özet Kitabı, 184, Antalya, 2008.
2.4.2.41. Dane F, Gümüş M, Yaman E, Öztürk MA, Sevinç A, Atasoy BM, Çabuk D,
İyikesici S, Yumuk PF, Başaran GA, Abacıoğlu U, Teomete M, Turhal NS, Küratif olarak
rezeke edilmiş evre II-III rektum kanserli Türk hasta populasyonunun adjuvan
kemoradyoterapi sonuçları, prognostik özellikleri ve sağkalım analizleri, çok merkezli
retrospektif çalışma. Marmara Üniversitesi Tıp Fakültesi 3. Araştırma Günleri, İstanbul,
Marmara Medical Journal 21(Ek 1) (2008), 9.
2.4.2.42. Öztürk MA, Dane F, Çelikel ÇA, Baş E, Çabuk D, Yumuk PF, Başaran GA.,
Teomete M ve Turhal NS, “Adjuvan Kemoradyoterapi alan Kolorektal Kanser
Hastalarında Survivinin Prognostik Önemi,” 18. Ulusal Kanser Kongresi, Bildiri Özet
Kitabı, P135, Antalya, 2009.
2.4.2.43. Dane F, Öztürk MA, Gümüş M, Çabuk D, Yumuk PF, Başaran G, Teomete M,
Korkmaz T, Şeber S, ve Turhal NS, “Metastatik Kolorektal Kanser Tedavisinde
Bevasizumab: Geç daha mı az etkin?,” 18. Ulusal Kanser Kongresi, Bildiri Özet Kitabı,
P139, Antalya, 2009.
2.4.2.44. Dane F, Demir G, Öztürk MA, Yeğen C, Çabuk D, Başaran G, Yumuk PF,
Teomete M, Korkmaz T, Şeber S ve Turhal NS, “Karaciğer ve akciğer metastazlı
kolorektal kanser hastalarında cerrahi rezeksiyon sonuçları,” 18. Ulusal Kanser Kongresi,
Bildiri Özet Kitabı, P149, Antalya, 2009.
2.4.2.45. Atasoy BM, Dane F, Akgün Z, Çabuk D, Kabalay İA, Yumuk PF, Çağlar H,
Turhal NS ve U Abacıoğlu, “Lokal ileri evre nazofarenks kanserinde dosetaksel ile
sisplatin bazlı indüksiyon kemoterapisi sonrası sisplatinle eş zamanlı kemoradyoterapi:
Sağkalım ve yan etki değerlendirmesi,” 18. Ulusal Kanser Kongresi, Bildiri Özet Kitabı,
P236, Antalya, 2009.
2.4.2.46. Turhal NS, PF Yumuk, MS iyikesici, F Dane, G Başaran, M Ekenel, Bruce
Avery. Knoxville, tennessee USA’de Evre III ve IV küçük hücreli dışı akciğer kanserli
37
hastaların sonuçları. 18. Ulusal Kanser Kongresi, Bildiri Özet Kitabı, Ref 812; 72, Antalya,
2009
2.4.2.47. Adjuvan kemoradyoterapi (AKRT) alan kolorektal kanser (KRK) hastalarında
survivinin prognostik önemi. Öztürk MA, Dane F, Demirel ÇA, Baş E, Çabuk D, Yumuk
PF, Başaran G, Teomete M, Turhal NS, Marmara Üniversitesi Tıp Fakültesi 3. Araştırma
Günleri, İstanbul, Marmara Medical Journal 22(1)(Ek 1) (2009), 6.
2.4.2.48. Basaran GA, Şeber S, Çabuk D, Korkmaz T, Turhal NS, Dane F, Başaran M,
Koçak M, Telli F, Yumuk F. Erken evre meme kanserli hastalarda adjuvan trastuzumab
tedavisi alan hastalarımızın klinik seyri. III. Tıbbi Onkoloji Kongresi Bildiri Kitabı, Poster
150, sayfa 97; 24-28 Mart 2010 Antalya
2.4.2.49. Şeber ES, Başaran G, Çabuk D, Korkmaz T, Koçar M, Telli F, Dane F, Yumuk
F, Turhal NS. Trastuzumab sonrası progrese olan metastatik meme kanseri
hastalarımızda lapatinib kullanımı. Erken evre meme kanserli hastalarda adjuvan
trastuzumab tedavisi alan hastalarımızın klinik seyri. III. Tıbbi Onkoloji Kongresi Bildiri
Kitabı, Poster 121, sayfa 84; 24-28 Mart 2010 Antalya
2.4.2.50. Çabuk D, Başaran G, Dane F, Korkmaz T, Şeber S, Telli F, Yumuk F, Turhal
NS, metastatik meme kanseri hastalarının kl,inik özellikleri ve sağkalım sonuçları: Tek
merkez deneyimi. III. Tıbbi Onkoloji Kongresi Bildiri Kitabı, Poster 146 sayfa 95; 24-28
Mart 2010 Antalya
2.4.2.51. Dane F, Öztürk MA, Ozkan M, Yıldız OG, Yaman E, Sevinç A, Atasoy BM,
Gümüş M, Koçar M, Başaran G, Yumuk PF, Turhal NS. Günlük pratikte tedavi alan
rektum kanseri hastalarının demografik sağkalım ve klinik/patolojik özellikleri: retrospektif
bir kohort çalışması. VII. Ulusal Tıbbi Onkoloji Kongresi. Kongre Bildiri Kitabı. Poster 86,
sayfa 139, 22-26 Eylül 2010, Antalya,
2.4.2.52. Dane F, Öztürk MA, Koçar M, Çabuk D, Teomete M, Korkmaz T, Seber S, Telli
F, Kanıtez M, Başaran G, Yumuk PF, Turhal NS. Müsin varlığı evre II kolorektal
kanserlerde bağımsız bir risk faktörüdür. Kongre Bildiri Kitabı.poster no 88, sayfa 141 VII.
Ulusal Tıbbi Onkoloji Kongresi 22-26 Eylül 2010, Antalya,
2.4.2.53. Dane F, Öztürk MA, Atasoy BM, Gümüş M, Koçar M, Çabuk D, Teomete M,
Başaran G, Yumuk PF, Çelikel Ç, Turhal NS. Erken Evre rektum kanserlerinde perinöral
invazyonun prognostik önemi. Kongre Bildiri Kitabı poster no 89, sayfa 142. VII. Ulusal
Tıbbi Onkoloji Kongresi 22-26 Eylül 2010, Antalya,
2.4.2.54. Şeber ES, Başaran G, Korkmaz T, Telli F, Kocar M, Kanıtez M, Aktaş B, Dane
F, Yumuk PF, Turhal NS. Diyabetik Erken Evre Meme Kanserli Hastaların Klinik /
Patolojik Özellikleri ve Sağ kalım Verileri. Bildiri Özetleri, 19. Ulusal Kanser Kongresi 2024 Nisan 2011, Antalya. P 229
2.4.2.55. Aktas B, Dane F, Seber S, Telli F, Koçar M, Kanıtez M, Beşiroğlu M, Yumuk PF,
Turhal NS, Böbrek hücreli tümörde mide metastazı: Olgu sunumu. 4. Tıbbi Onkoloji
Kongresi. EP-266 Sf: 261 21-25 Mart 2012, Antalya
2.4.2.56. Seber S, Korkmaz T, Okutur K, Kanıtez M, Aktas B, Telli F, Koçar M, Beşiroğlu
M, Yumuk PF, Turhal NS, Metastatik Kolorektal Kanserinde Kemoterapi Öncesi Timidin
Kinaz Aktivite Düzeylerinin Prognostik Önemi. 4. Tıbbi Onkoloji Kongresi. EP-174 Sf: 220
21-25 Mart 2012, Antalya
38
2.4.2.57. Korkmaz T, Seber S, Aydın D, Ustaalioğlu B, Canhoroz M, Bilici A, Yıldız R,
Yaşar N, Ercelep Ö, Şener N, Güven A, Yüksel S, Yumuk PF, Kanat Ö, Gümüş M,
Turhal NS, Küçük Hücreli Akciğer Kanserinde 2. Basamak Tedavi Etkinliğinin Çok
Merkezli ve Retrospektif Olarak İncelenmesi. 4. Tıbbi Onkoloji Kongresi. EP-23 Sf: 151
21-25 Mart 2012, Antalya
2.4.2.58. Öztürk MA, Dane F, Karagöz S, Tural D, Turna H, Büyükünal E, Erdamar S,
Turhal NS, Serdengeçti S. Adjuvan Tedavi Verilen Kolorektal Kanserlerde (KRK)
Perinöral İnvazyonun (PNI) Hastalıksız Sağ Kalım (DFS) Açısından Önemi. 4. Tıbbi
Onkoloji Kongresi. S-11 Sf: 112 21-25 Mart 2012, Antalya
2.4.2.59. Koçar M, Dane F, Yumuk PF, Telli F, Seber S, Kanıtez M, Turhal NS,
Metastatik Böbrek Hücreli Kanserde Sunitinib Tedavisinin Etkinlik ve Yanetki Profilinin
Değerlendirilmesi. 4. Tıbbi Onkoloji Kongresi. EP-350 Sf: 299. 21-25 Mart 2012, Antalya
2.4.2.60. Hayran M, Kılıçkap S, Elkıran T, Akbulut H, Abalı H, Yüce D, Kılıç D, Turhal
NS, Kanserli Hasta Yakınlarında Sigara İçme Alışkanlıkları. 4. Tıbbi Onkoloji Kongresi.
EP-135 Sf: 201 21-25 Mart 2012, Antalya
2.4.2.61. Dane F, Atasoy BM, Akgün Z, Yumuk PF, Çabuk D, Teomete M, Başaran G,
Turhal NS, Abacıoğlu U. Evre III/IV Non Metastatik Nazofarenks Kanserinde Sisplatinle
Eş Zamanlı Kemoradyoterapi Öncesi Dosetaksel ile Sisplatin Bazlı İndüksiyon
Kemoterapisi. 4. Tıbbi Onkoloji Kongresi. SS-1 Sf: 102. 21-25 Mart 2012, Antalya
2.4.2.62. Yurtseven G, Yurt N, Aygün M, Turhal NS, Onkolojik Tedavi Sonrası Takibe
Uyum 4. Tıbbi Onkoloji Kongresi. HS-8 Sf: 136 21-25 Mart 2012, Antalya
39
Books written in Turkish
2.5.2.1. Turhal NS, “Antineoplastik İlaçları Kullanma Rehberi” İstanbul 1999.
2.5.2.2.
Books Chapters written in English
2.5.3.1. Biochemistry of Cancer, Medical Oncology Board Review, Williams &
Wilkins, Philadelphia 1-42 March 1997.
2.5.3.2. Lung Cancer, Medical Oncology Board Review, Williams & Wilkins,
Philadelphia 107-209 March 1997.
2.5.3.3. Turhal NS, Yumuk PF, “Tumor markers in neuroendocrine tumors of the
gastroenteropancreatic system” İstanbul, 2004.
Book Chapters written in Turkish
2.5.4.1. Gümüş M, Atalay G, Aliustaoğlu M, Turhal NS, “Kolorektal Kanser
(Bağırsak Kanseri) Hasta El Kitabı, İstanbul, 2000.
2.5.4.2. Atalay G, Aliustaoğlu M, Gümüş M, Turhal NS, “Meme Kanseri Hasta El
Kitabı”, İstanbul, 2001.
2.5.4.3. Aliustaoğlu M, Gümüş M, Atalay G, Turhal NS, “Akciğer Kanseri Hasta El
Kitabı”, İstanbul, 2001.
2.5.4.4. Turhal NS, “Özafagus kanserinde kemoterapi ve kemoradyoterapi
uygulamaları” Özafagus hastalıklarının tıbbi ve cerrahi tedavisi, ed. Prof. Dr. Mustafa
Yüksel, Prof. Dr. Ahmet Başoğlu, 321-329, İstanbul 2002.
2.5.4.5. Turhal NS, “Yüksek riskli gestasyonal trofoblastik tümörlerin tedavisi”,
Jinekolojik Kanserlerde Tedavi, ed. N.M. Mandel ve M. Özgüroğlu, 89-96, Frekans,
İstanbul, 2004.
2.5.4.6. Dane F, Ekenel M, Başaran G, İyikesici MS, Yumuk PF, Karamanoğlu A,
Turhal NS. “Onkoloji Hastalarında Beslenme ve Egzersiz Rehberi” İstanbul 2004.
40
International Panelist/Speaker
2.7.1.1. “Approach to Colorectal cancer in Balkans”, Balkan Congress of Oncology,
Serbia/Beograd, September 2004
2.7.1.2. “Current Approach to Hepatocellular Cancer” Hazar University
Multidisiplinary liver disease meeting. Azerbaijan/Bakü, November 2004
2.7.1.3 “Current Treatment of Non-Hodgkin Lymphomas” King Faisal Medical
Center. Saudi Arabia/Riyadh November 2005
2.7.1.4. “New approaches to the treatment of brain metastasis” Turkish-Hellenic
ESMO Advanced Course. Recent Advances in the Treatment of Cancer.
Turkey/Istanbul, December 2005
2.7.1.5. “Applications of Regenerative Medicine in Turkey” Regional Health
Conference “Balkan Medicine towards New Millenium” Romania/Bcharest, May
2006
2.7.1.6. “New Research Efforts for Metastatic Gastric Cancer” EORTC
Gastrointestinal Tract Cancer Collaborative Group, France/Paris, May 2006
2.7.1.7. Moderator, Balkan School of Oncology, Second Seminar for Molecular
Oncology in Cancer. Greece/Volos September 2007.
2.7.1.8. Moderator, Innovative Therapetic Approaches in Non-Colorectal Cancer,
European Organization for research and Treatment of Cancer Gastrointestinal Tract
Cancer Collaborative Group, Germany/Mainz November 2007
2.7.1.9. Moderator, Rare Gastrointestinal Tumors, Turkish-Hellenic 3rd ESMO
Advanced Course Turkey/Istanbul December 2007
41
National Panelist/Speaker:
2.7.2.1. “Meme kanserinin kemik metastazlarının tedavisi”, Türk Kanser ile Savaş
Cemiyeti Toplantısı, İstanbul, Temmuz 1998
2.7.2.2. “Meme kanserinin adjuvan hormon tedavisi”, İstanbul Onkoloji Grubu Meme
Kanseri Konsensus Paneli, İstanbul, Şubat 1999
2.7.2.3. “Rezeke edilmiş akciğer kanserinde adjuvan kemoterapi” İstanbul Onkoloji
Grubu Akciğer Kanseri Konsensus Paneli, İstanbul, Mart 1999
2.7.2.4. “Meme kanseri lokorejyonel relapsının tedavisi” Cerrahpaşa Tıp Fakültesi,
İstanbul, Mayıs 1999.
2.7.2.5. “Over kanserinde optimal adjuvan tedavi” İstanbul Onkoloji Grubu
Jinekolojik Tümörler Konsensus Paneli, İstanbul Mart 2000
2.7.2.6. “Meme kanserinde neo adjuvan kemoterapi”, Gülhane Askeri Tıp Akademisi
Toplantısı, Ankara, Mayıs 2000
2.7.2.7. “HIV Kanserlerine Hemşire Yaklaşımı” Marmara Üniversitesi Onkoloji
Hemşireliği Konferansı, İstanbul, Ekim 2000
2.7.2.8. “Küratif rezeke akciğer kanserinde takip” Türk Göğüs Hastalıkları Derneği
İstanbul, Şubat 2001
2.7.2.9. “Rezeke edilmiş küçük hücreli dışı akciğer kanserinde takip” İstanbul
Onkoloji Grubu Akciğer Kanseri Konsensus Paneli, İstanbul, Şubat 2001
2.7.2.10. “Duktal karsinoma insituda adjuvan tamoxifenin rolü” Cerrahpaşa Tıp
Fakültesi Meme Toplantıları İstanbul, Nisan 2001
2.7.2.11. “Meme kanserinde seçici estrojen reseptör modülatörlerinin rolü”, Türk
Meme Cemiyeti, İstanbul, Eylül 2001
2.7.2.12. “HIV kanserlerine hemşire yaklaşımı” Marmara Üniversitesi Tıp Fakültesi
Ulusal Onkoloji Hemşireliği Konferansı, İstanbul, Ekim 2001
2.7.2.13. “Metastatik mesane kanserinin tedavisi” Dr. Lütfi Kırdar Kartal Eğitim ve
Araştırma Hastanesi Tıp Günleri “Onkoloji” İstanbul, Kasım 2001
2.7.2.14. “Meme kanserinin biyolojik tedavileri” Gülhane Askeri Tıp Akademisi
Onkoloji Toplantısı, Ankara, Haziran 2002
2.7.2.15. “Erişkinlerde hodgkin hastalığının tedavisi”, Ulusal Kanser Kongresi,
Antalya, Nisan 2003
2.7.2.16. “Disfajinin kanser hastalarındaki tedavisi”, Türk Onkoloji Grubu Toplantısı,
Ankara, Mayıs 2003
42
2.7.2.17. “Uluslar arası kanser araştırmalarına katılımdaki güçlükler”, Meme Bilimi
(Senoloji) Derneği, İstanbul, Eylül 2003.
2.7.2.18. “Meme kanserinin sistemik tedavisi”, VII. Ulusal Meme Hastalıkları
Kongresi, Antalya, Ekim 2003
2.7.2.19. “Gastroözafageal kanserlerde süren araştırma projeleri”, Sindirim Sistemi
Kanserleri Çalışma Grubu Toplantısı, İzmir, Aralık 2003
2.7.2.20. “Mide kanserinin adjuvan tedavisi” Türk Onkoloji Grubu Toplantısı, Oturum
başkanlığı, Antalya, Aralık 2003
2.7.2.21. “Kadınlarda sık görülen kanser türleri ve erken tanı” Marmara Üniversitesi,
Hemşirelik Müdürlüğü, 2004 Yılı Hizmet içi Eğitim Programı, İstanbul, Şubat 2004.
2.7.2.22. “Onkolojiye Giriş”, Haydarpaşa Numune Hastanesi Devamlı Eğitim
Toplantıları, İstanbul, Mart 2004
2.7.2.23. “Yüksek riskli gestasyonel trofobilastik tümörlerde kemoterapi”, Türk
Onkoloji Derneği Sürekli Eğitim Toplantıları, Adana, Nisan 2004
2.7.2.24. “Kanser ve mesleki maruziyet” Meslek Hastalıkları ve İş Kazaları Kongresi,
İstanbul, Nisan 2004
2.7.2.25. “HIV ve hodgkin dışı lenfoma”, Türk Pediatrik Onkoloji Kongresi, Kayseri,
Mayıs 2004.
2.7.2.26. “Terminal kanser hastalarında bulantı tedavisi”, Uluslararası Kanser
Hastalarında Palyatif Bakım Kongresi, İstanbul, Eylül 2004.
2.7.2.27. “Beslenme ve mide kanseri” Tıbbi Onkoloji Derneği, Mide tümörleri
Sempozyumu” İstanbul, Aralık 2004.
2.7.2.28. “Lokal ileri meme kanserinde güncel tedavi yaklaşımları” İstanbul Tıp
Fakültesi Meme Grubu IX. Mezuniyet Sonrası Eğitim Kursu İstanbul, Aralık 2004.
2.7.2.29. “Primeri bilinmeyen hastaya yaklaşım” XVI. Ulusal Kanser Kongresi.
Antalya, Nisan 2005.
2.7.2.30. “Etiology, pathogenesis, treatment and follow –up” 22. Ulusal
Gastroenteroloji Haftası. Malatya, Eylül 2005
2.7.2.31. “Meme kanseri riskinin değerlendirilmesi ve korunma” VIII. Ulusal Meme
Hastalıkları Kongresi. İstanbul, Eylül 2005
2.7.2.32. “First line chemotherapy in advanced gastric cancer” 1. Ulusal Onkolojik
Araştırmalara çalıştayı ve TOG Alt Çalışma Grupları Toplantısı. Ankara, Aralık 2005
43
2.7.2.32. “Küçük Hücreli Dışı Akciğer Kanserleri-Lokal İleri Evre, Kemoterapi”
Akciğer, Meme, Gastrointestinal Sistem Kanserlerinde Konsensus Toplantısı. İstanbul,
Mart 2006
2.7.2.33. “Evre II Kolon Kanserinde Adjuvan Kemoterapi Gerekli mi?” I. Tıbbi
Onkoloji Kongresi. Antalya, Mart 2006
2.7.2.34. Bilimsel Kurul. İstanbul Meme Kanseri Konferansı. İstanbul, Eylül 2006.
2.7.2.34. “Disiplinlerin Birbirlerinden Beklentileri” TAKD II. Ulusal Akciğer Kanseri
Kongresi. Antalya, Kasım 2006
2.7.2.35. “Tedavi Uygulamalarına Bağlı Sorunlar” Oturum Başkanı. 5. İstanbul
Üniversitesi Onkoloji Enstitüsü Günleri. Antalya, 30 Kasım – 3 Aralık 2006.
2.7.2.36. “Kolorektal Dışı Gastrointestinal Tümörlerde Hedefe Yönelik Tedaviler”
Tıbbi Onkoloji Derneği, Aralık 2006.
2.7.2.36. “Yeni Prognostik Faktörler ve Hedefe Yönelik Tedaviler” 3. Ulusal Torasik
Onkoloji Kongresi. Marmaris, Haziran 2007.
2.7.2.37. Bilimsel Kurul. 9. Ulusal Meme Hastalıkları Kongresi. .Ankara Eylül 2007
44
International Meeting Organizations
2.8.1.1. Uluslararası Kanser Hastalarında Palyatif Bakım Kongresi, İstanbul, Eylül
2004.
2.8.1.2. European Organization for Research and Treatment of Cancer Gastrointestinal
Study Group Meeting Istanbul Turkey 2005
2.8.1.3. Balkan Union of Oncology Biannual Meeting Izmır Turkey 2008
National Meeting Organizations
2.8.2.1. Marmara Üniversitesi Onkoloji Hemşireliği Konferansı, İstanbul, Ekim 2000
2.8.2.2. Marmara Üniversitesi Tıp Fakültesi Ulusal Onkoloji Hemşireliği Konferansı,
İstanbul, Ekim 2001
45
Collaboration in National Research Projects
3.1.2.1. Mide kanserli hastaların yaşam kalitesini değerlendirmede EORTC QLQ-C30
ve hastalığa özel anket modülü olan (QLQ-STO 22)' nin güvenirlilik ve gerçekliği
üzerine uluslararası bir saha araştırması, EORTC 15001/40003, Sorumlu Araştırmacı,
2002.
3.1.2.2. Rezeke edilemeyen karaciğer metastazlı kolorektal kanser hastalarında
irinotekan+fluorouracil/leukovorin kombinasyon tedavisi sonrası rezeke edilebilirlik
hızının değerlendirildiği klinik çalışma, çok merkezli TOD çalışması, Sorumlu
Araştırmacı 2003.
3.2.2.1. Daha önce bir veya iki kemoterapi rejimi uygulanmış olan, ancak en son
uygulanan kemoterapi rejimine cevap vermemiş ya da bu rejimi tolere edememiş, ileri
evre, küçük hücreli-dışı akciğer kanserli hastalarda ZD1839 (IressaTM) (250mg tablet)
+ en iyi destek tedavisi kombinasyonunu, plasebo + en iyi destek tedavisi
kombinasyonuyla karşılaştıran, plasebo kontrollü, çok-merkezli, randomize, faz III sağ
kalım çalışması, Iressa/709 (ISEL) çalışması, Yardımcı Araştırmacı, 2003. Puan: 15
3.2.2.2. Adjuvan Kemoradyoterapi Uygulanan Rektum Kanserli Hastalarda Yaşam
Kalitesinin Değerlendirilmesi, Faz IV, Ulusal, Çok Merkezli Çalışma, Yardımcı
Araştırmacı, 2003.
3.2.2.3. Haftalık Paclitaxel ve Carboplatin tedavisi almış olan evre IIIA/B, IIIB
(plevral effüzyonlu) ve IV küçük hücreli dışı akciğer kanseri hastalarında Her 2-neu
ve TP53 tümör supressör geninin hastaların prognozuna katkıları olup olmadığının
incelenmesi, Yardımcı Araştırmacı, 2004.
3.2.2.4. İndiferansiye ve Non-Keratinize Skuamöz Hücreli Nazofarenks Kanserinde
Dosetaksel-Sisplatin Neoadjuvan Tedavisi Sonrası Kemoradyoterapi Uygulamasının
Etkinliğinin Değerlendirildiği Faz IV Klinik Çalışma, TOG Baş-Boyun Grubu
Çalışması, Ulusal, Çok Merkezli Çalışma, Yardımcı Araştırmacı, 2004.
3.2.2.5. Anastrazol (Arimidex) kullanan erken evre meme kanseri hastalarında
elektronik farmakovijilans çalışması, Yardımcı Araştırmacı, 2004.
3.2.2.6. Taxotere ve Sisplatin ile birinci basamak kemoterapiyi takiben küçük hücreli
olmayan akciğer kanserinin tedavi stratejisine ilişkin gözlem çalışması
XRP6976C/9001 Yardımcı Araştırmacı, 2004.
46
Collaboration in International Research Projects
3.2.1.1. Çok merkezli yüksek doz infüzyonel 5-FU±Folinik asit ile bolus 5-FU/folinik
asitin karşılaştırıldığı randomize faz III çalışması, EORTC PETACC-2, Marmara
Üniversitesi için Sorumlu Araştırmacı, 2002
3.2.1.2. 35 yaş altı meme tümörlü hastaların adjuvan tedavilere bağlı fertilite kaybı
riskine karşı tutumlarını değerlendirmeye yönelik Uluslararası Meme Grubunun ölçme
çalışması, EORTC 10002, Marmara Üniversitesi için Sorumlu Araştırmacı, 2003.
3.2.1.3. Daha önce tedavi almamış ve platinum ile etoposid verilecek ekstensif evre
küçük hücreli akciğer kanserli hastalarda darbopoetin alfa kullanımının etkisini ölçen
randomize, çift-kör, plasebo kontrollü çalışma, Marmara Üniversitesi için Sorumlu
3.2.1.4.
FACT:
Anastrozol
Monotherapisi
ile
Anastrozol+Fulvestrant
kombinasyonuyla sağlanan maksimal östrojen blokajının karşılaştırılması: Hormon
reseptörü pozitif meme kanseri olan ve lokalize tümörün primer tedavisinden sonra ilk
defa nüks gelişen postmenapozal kadınlarda yalpan açık, randomize, karşılaştırmalı,
çok merkezli faz III çalışma, Protokol no: 9238SW/0001, Uluslararası, Çok Merkezli
Çalışma, Marmara Üniversitesi için Sorumlu Araştırmacı 2004.
3.2.1.5. Lokal olarak gelişmiş veya metastatik meme kanseri olan postmenapozal
kadınlarda birinci seçenek hormon tedavisinde letrozol ile kombine olarak oral CCI779’a karşı tek başına letrozol uygulamasının karşılaştırıldığı bir faz III randomize
plasebo kontrollü, çift kör çalışma, Protokol no: 3066A1-303-WW, Marmara
Üniversitesi için Sorumlu Araştırmacı, 2004.
3.2.1.6. Menapoz sonrası metastatik meme kanseri hastalarında ilk seçim hormonal
tedavi olarak exemestane ile tamoxifen kullanımının karşılaştırılması, randomize faz
III çalışma, (EORTC Protokol No: 10951) Marmara Üniversitesi için Sorumlu
3.2.1.7. Hormona duyarlı meme kanseri olan premenopozal kadınlarda adjuvan tedavi
olarak over fonksiyonunun baskılanması ve exemestanın rolünü değerlendiren bir faz
III randomiz çalışma. Suppression of ovarian function trial (SOFT), Intergrup faz III
çalışması; IBCSG 24-02, BIG 2-02, EORTC Protokol no 10031), Marmara
Üniversitesi için Sorumlu Araştırmacı, 2004.
3.2.1.8. Post menapozal metastatik meme kanserinde birinci basamak tedavisi olarak
Letrozol ile kemoendokrin tedavisinin eş zamanlı ve sıralı kullanımının Letrozol’ün
tek ajan olarak kullanımıyla karşılaştırıldığı randomize çok merkezli çalışma; CFEM
345 C 2402 Marmara Üniversitesi için Sorumlu Araştırmacı, 2004.
3.2.1.9. Taksanlar ve Antrasiklin terapisinden sonra ilerleyen metastatik meme
kanserli hastalarda 3 haftalık siklüslerde 2 hafta süreyle günde iki defa uygulanan
kapesitabin (Xeloda) tabletleri ile 3 haftada bir IV uygulanan RPR109881’in
karşılaştırıldığı randomize faz III çalışması. Marmara Üniversitesi için Sorumlu

Nazim Serdar Turhal M

Transkript

Benzer belgeler

özgeçmiş ve eserler listesi

TÜRKİYE JEOLOJİSİNDE PALEOZOYİK OLUŞUKLAR

CURRICULUM VITAE Name : Ugur SELEK